Citation: Periferakis, A.; Periferakis, K.; Badarau, I.A.; Petran, E.M.; Popa, D.C.; Caruntu, A.; Costache, R.S.; Scheau, C.; Caruntu, C.; Costache, D.O. Kaempferol: Antimicrobial Properties, Sources, Clinical, and Traditional Applications. Int. J. Mol. Sci. 2022, 23, 15054. https://doi.org/10.3390/ijms232315054

Academic Editor: Mattia Falconi

Received: 31 October 2022
Accepted: 26 November 2022
Published: 30 November 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

**Abstract:** Flavonoids are a category of plant-derived compounds which exhibit a large number of health-related effects. One of the most well-known and studied flavonoids is kaempferol, which can be found in a wide variety of herbs and plant families. Apart from their anticarcinogenic and anti-inflammatory effects, kaempferol and its associated compounds also exhibit antibacterial, antifungal, and antiprotozoal activities. The development of drugs and treatment schemes based on these compounds is becoming increasingly important in the face of emerging resistance of numerous pathogens as well as complex molecular interactions between various drug therapies. In addition, many of the kaempferol-containing plants are used in traditional systems all over the world for centuries to treat numerous conditions. Due to its variety of sources and associated compounds, some molecular mechanisms of kaempferol antimicrobial activity are well known while others are still under analysis. This paper thoroughly documents the vegetal and food sources of kaempferol as well as the most recent and significant studies regarding its antimicrobial applications.

**Keywords:** kaempferol; molecular mechanisms; antibacterial; antiprotozoal; antifungal; herbal medicine

1. Introduction

In general, natural substances have been a recent target of research for their numerous health benefits and also for their potential as the basis for new drugs [1–3]. The use of plants and herbs is documented by numerous authors both in Europe [4] and elsewhere [5–8]. The aim of such research is two-pronged, both to explore new opportunities for effective

---

**Review**

**Kaempferol: Antimicrobial Properties, Sources, Clinical, and Traditional Applications**

_Argyrios Periferakis_1,2,†, Konstantinos Periferakis_2,3,4,†, Ioana Anca Badarau_1, Elena Madalina Petran_5,6,*, Delia Codruta Popa_5,7,*, Ana Caruntu_8,9,*, Raluca Simona Costache_10,11,*, Cristian Scheau_1,*, Constantin Caruntu_1,12, and Daniel Octavian Costache_13*

**1. Department of Physiology, The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania**

**2. Akadimia of Ancient Greek and Traditional Chinese Medicine, 16675 Athens, Greece**

**3. Pan-Hellenic Organization of Educational Programs (P.O.E.P), 17236 Athens, Greece**

**4. Orasis Acupuncture Institute, 11526 Athens, Greece**

**5. Department of Biochemistry, The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania**

**6. Department of Toxicology, Grigore Alexandrescu Emergency Children’s Hospital, 011743 Bucharest, Romania**

**7. Department of Hematology, Fundeni Clinical Institute, 022328 Bucharest, Romania**

**8. Department of Oral and Maxillofacial Surgery, ‘Dr. Carol Davila’ Central Military Emergency Hospital, 010825 Bucharest, Romania**

**9. Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, ‘Titu Maiorescu’ University, 031593 Bucharest, Romania**

**10. Department of Gastroenterology, Gastroenterology and Internal Medicine Clinic, ‘Dr. Carol Davila’ Central Military Emergency Hospital, 010825 Bucharest, Romania**

**11. Department of Internal Medicine and Gastroenterology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania**

**12. Department of Dermatology, Prof. N.C. Paulescu’ National Institute of Diabetes, Nutrition and Metabolic Diseases, 011233 Bucharest, Romania**

**13. Department of Dermatology, ‘Dr. Carol Davila’ Central Military Emergency Hospital, 010825 Bucharest, Romania**

* Correspondence: delia.popa@umfcd.ro (D.C.P.); cristian.scheau@umfcd.ro (C.S.)
† These authors contributed equally to this work.

---

**1. Introduction**

In general, natural substances have been a recent target of research for their numerous health benefits and also for their potential as the basis for new drugs [1–3]. The use of plants and herbs is documented by numerous authors both in Europe [4] and elsewhere [5–8]. The aim of such research is two-pronged, both to explore new opportunities for effective
therapeutical agents, and also to elucidate the correlation between a decreased incidence of health problems and the consumption of certain food types. Regarding this last aim, it is the logical course of action, since certain diets are correlated with negative mortality and morbidity incidence rates [9–13]—in addition, based on the research of [14] specific diet choices after the diagnosis of cancer may improve survival rates.

The focus of this paper is kaempferol, (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one), a flavonoid with many promising health benefits found in a variety of plants. Kaempferol is named in honor of Engelbert Kaempfer, a German doctor, naturalist, and historian who lived during the 17th century and made a significant contribution to transporting medical knowledge from Japan to the West [15]. Kaempferol, as a chemical compound, was discovered in Camelia sinensis (tea tree) [16] and exhibits a host of different positive health-related effects.

In this review, we will present a thorough view of the studies which have aimed to ascertain the use of kaempferol against pathogens, namely protozoa, fungi and bacteria, describing the molecular mechanisms of action, where literature data is available. We will also explain the relative importance of the pathogens described to justify the importance of the studies on kaempferol as a novel basis for therapies and drug design. A number of these researches have focused on the extracts of plants that are included in traditional medical systems in different countries and regions. Accordingly, we will also describe the traditional use of kaempferol-containing plants and we will also present the most prominent plant species which contain kaempferol in regard to biosynthesis and availability of the substance.

2. Biosynthesis and Availability of Kaempferol

Kaempferol is a flavonoid; flavonoids are regarded as the largest group of secondary plant metabolites. They are polyphenolic compounds of low molecular weight and are used by plants to stimulate and regulate their growth and for defense purposes [17]. Flavonoids are divided into a number of groups based on their chemical composition, namely flavones, flavonols, flavanones, isoflavonoids, catechins (flavanols), anthocyanins and chalcones [18]. The antioxidant properties of polyphenols—flavonoids are such compounds—are already well known [19]; more than $10^4$ types of flavonoids are estimated to exist [20,21]. Other proven effects of flavonoids include hepatoprotective [22–24], antimicrobial [25,26], renoprotective [27,28], antidiabetic [29,30], cardioprotective [31,32], anti-arthritic [33], neuroprotective [34–37], gastroprotective [38,39] and anti-mutagenic [40–44], among others [16].

Recently, there has been an increasing amount of research interest in the anti-carcinogenic potential of kaempferol [45,46], as a positive correlation between its consumption and reduced cancer incidence has been documented [47]; this is in addition to existing epidemiological studies linking increased flavonoid consumption with reduced cancer incidence [48,49]. The anti-inflammatory role of kaempferol has also been concisely presented by [50], while even its anti-adipogenic potential has come under investigation [51].

The basic structure of all flavonoids, regardless of their subclass, is a 15-carbon benopyranone or benzopyran in which the three-carbon bridge between the phenyl groups is commonly cyclized with oxygen forming a C6-C3-C6 flavan nucleus [19,52,53].

Kaempferol is specifically classified as a flavonol [54] and has the molecular formula C15H10O6 (Figure 1).

![Figure 1. The two-dimensional structural formula of kaempferol.](image-url)
2.1. Biosynthetic Pathways of Kaempferol

Flavonoids are synthetized via the shikimic acid pathway [55], a process that occurs in the plants’ plastids [56–58]. More than 2000 compounds are known, with nearly 500 occurring in a free-aglycone state and the rest as O- or C-glycosides. Flavonols, in their free forms as aglycones, have lipophilic properties, yet most flavonols produced in plants are attached to a sugar moiety, the glycoside form, and are water-soluble [59]. The hydroxyl functional groups present in each flavonol are potential sites for linkage to saccharides as O-glycosides [60]. The saccharides most commonly attached to flavonols are monosaccharides such as glucose, rhamnose, galactose, arabinose, and xylose [32], and the disaccharide rutinose (glucose and rhamnose connected by a β-glycosidic bond) [61].

2.2. Bioavailability of Kaempferol

The pharmacokinetics of kaempferol has been studied in vitro and in vivo, both in rats and humans. Flavonols such as kaempferol are commonly ingested as glycosides. The types and attachments of saccharide impact bioavailability, and also bioactivity [62]. Glycosides are highly polar compounds, a property that greatly impacts their absorption, whereas the intermediate polarity of aglycones facilitates it. For some types of glycosides, previous hydrolysis to absorbable aglycones is needed, and others can be absorbed without hydrolysis [54].

Like other flavonoids, kaempferol is mainly absorbed in the small intestine. The lipophilicity of aglycone kaempferol facilitates its absorption by passive diffusion, but evidence suggests that it can also be absorbed by facilitated diffusion or active transport [63]. The nature of sugar linking will influence the compound uptake, as enterocytes have a preference for glucose, as membrane-bound beta-glucosidase breaks down the glucoside before absorption [64]. Kaempferol glucosides with many sugar units in their structure travel to the large intestine, where gut microbiota will remove terminal saccharides exposing the glucose, and then absorption by enterocytes occurs [65]. Studies have shown that kaempferol-O-glycosides decomposition can be extended to a breakdown process known as C-ring fission (C-ring is the central ring of the flavonoid structure) to form simple phenolic compounds such as 4-hydroxyphenylacetic acid, phloroglucinol and 4- methylphenol, which can either be absorbed or excreted in feces [66–68].

After absorption, conjugated forms of kaempferol, some phenolic compounds produced by the colon microflora, kaempferol, and some kaempferol glycosides can reach systemic circulation and tissues and are transported along with intestinal metabolites to the liver, where a part of them are metabolized (mainly compounds with poor hydro solubility). In the liver, and also in enterocytes, metabolism involves the phase I (oxidation and O-demethylation) and the phase II pathway (sulfation, glucuronidation, and methylation) followed by distribution to body tissues and urine excretion [69–71].

Pure kaempferol can be isolated from several plant species (Table 1), in the Divisions Pteridophyta, Coniferophyta, and Angiosperms of the Kingdom Plantae [72]. In addition, the glycosides of kaempferol can be identified in many plant families [73–80]—a detailed account of the various kaempferol chemical compounds and derivatives may be found in recent studies [54]. The kaempferol content of some common foodstuffs is provided in Table 2.

### Table 1. Plant species containing pure kaempferol [54,81–83].

| Clade                        | Order   | Family    | Species                  | Reference |
|------------------------------|---------|-----------|--------------------------|-----------|
| Gymnosperms, Tracheophytes   | Pinales | Taxaceae  | Taxus baccata            | [77]      |
| Mesangiosperms, Magnoliids   | Canellales | Canellaceae | Warburgia stuhlmannii    | [84]      |
|                              | Magnoliales | Annonaceae | Annona cherinola Miller  | [85]      |
| Clade                  | Order                | Family          | Species              | Reference |
|-----------------------|----------------------|-----------------|----------------------|-----------|
| Mesangiosperms, Monocots | Asparagales         | Alliaceae       | Allium cepa          | [86]      |
|                       | Asphodelaceae        | Aloe vera       |                      | [87]      |
| Liliales              | Liliaceae            | Lilium candidum |                      | [88]      |
|                       | Smilacaceae          | Smilax bockii   |                      | [90]      |
| Ranunculales          | Berberidaceae        | Dipsosma versipellis |                | [91]      |
|                       | Ranunculaceae        | Consolida oliveriana |            | [92]      |
| Saxifragales          | Crassulaceae         | Orostachys japonicus |              | [93]      |
|                       |                      | Rhodiola rosea  |                      | [94]      |
|                       |                      | Rhodiola sachalinensis |           | [95]      |
|                       |                      | Kalanche fedtschenkoi |           | [96]      |
| Vitales               | Vitaceae             | Parthenocissus tricuspidata |         | [97]      |
|                       |                      | Cayratia trifolia Linn |          | [98]      |
| Cucurbitales          | Cucurbitaceae        | Gynostemma cardiospermum |    | [99]      |
|                       |                      | Astragalus creticus Lam. |        | [100]     |
|                       |                      | Tylosena esculentum |                      | [101]     |
|                       |                      | Bauhinia vahlisi |                      | [102]     |
|                       |                      | Acacia nilotica  |                      | [103]     |
|                       |                      | Ambrurana caerensis |                       | [104]     |
|                       |                      | Cassia angustifolia |                   | [105]     |
|                       |                      | Cassia siamea    |                      | [106]     |
|                       |                      | Indigofera suffruticosa |                | [107]     |
|                       |                      | Indigofera truxilensis |              | [107]     |
|                       |                      | Oxytropis falcate |                      | [108]     |
|                       |                      | Securigera securidaca |               | [109]     |
|                       |                      | Tadehagi triquetrum |                 | [110]     |
|                       |                      | Trifolium alexandrinum |             | [111]     |
|                       | Fabaceae             | Elaeagnaceae    | Hippophae rhamnoides | [112]     |
|                       |                      | Rhamnaceae      | Rhamnus nakaharai   | [113]     |
|                       |                      | Rhamnus procumbens |                     | [114]     |
|                       | Rosaceae             | Prunus davidiana |                      | [115]     |
|                       |                      | Rosa spp.       |                      | [116]     |
|                       |                      | Rosa damascena  |                      | [117]     |
|                       |                      | Rosa hybrids    |                      | [118]     |
|                       | Ulmaceae             | Zelkova oregoniana |                | [119]     |
|                       | Celastrales          | Celastraceae    | Euonymus alatus     | [120]     |
|                       |                      | Hypericum brasilense |              | [121]     |
|                       | Malpighiales         | Clusiaceae      | Hypericum perforatum | [122]     |
|                       |                      | Hypericum perforatum |              | [122]     |
|                       |                      | Vismia laurentii |                      | [123]     |
| Clade                          | Order          | Family            | Species                        | Reference |
|-------------------------------|----------------|-------------------|--------------------------------|-----------|
| Malpighiales                  | Euphorbiaceae  |                   | Elateriospermum tapos          | [124]     |
|                               |                |                   | Euphorbia aleppica            | [125]     |
|                               |                |                   | Phyllanthus acidus             | [126]     |
|                               |                |                   | Sauropus androgynus           | [127]     |
|                               |                |                   | Sebastiania brasiliensis      | [128]     |
|                               | Salicaceae     |                   | Populus davidiana            | [129]     |
| Geraniales                    | Geraniaceae    |                   | Geranium carolinianum         | [130]     |
|                               |                |                   | Geranium potentillaefolium    | [131]     |
|                               |                |                   | G. ibericum subs. jubatum     | [132]     |
|                               |                |                   | Pelargonium quercifolium      | [133]     |
|                               | Brassicales    | Brassicaceae      | Brassica rapa                 | [134]     |
|                               |                |                   | Bunias orientalis             | [135]     |
|                               |                |                   | Diplotaxis erucoides          | [135]     |
|                               |                |                   | Diplotaxis tenuifolia         | [135]     |
|                               | Cistaceae      |                   | Helianthemum glomeratum       | [136]     |
| Malvalves                     | Malvaceae      |                   | Althaea rosea                 | [137]     |
|                               | Sterculiaceae  |                   | Theobroma grandiflorum        | [138]     |
|                               | Tiliaceae      |                   | Tilia tomentosa               | [139]     |
| Mesangiosperms, Eudicots      | Combretaceae   |                   | Combretum erythrophyllum      | [140]     |
|                               | Lythraceae     |                   | Cuphea pinetorum              | [141]     |
|                               |                |                   | Eucalyptus spp.               | [142]     |
|                               | Myrtaceae      |                   | Psidium guajava               | [143]     |
|                               |                |                   | Syzygium aromaticum           | [144]     |
|                               | Punicaceae     |                   | Punica granatum               | [145]     |
| Myrtales                      | Anacardiaceae  |                   | Pistacia vera                 | [146]     |
|                               | Sapindaceae    |                   | Rhus verniciflua              | [147]     |
|                               | Simaroubaceae  |                   | Simarouba versicolor          | [150]     |
| Caryophyllales                | Amaranthaceae  |                   | Alternanthera tenella         | [151]     |
|                               | Nepenthaceae   |                   | Nepenthes gracilis            | [152]     |
|                               | Polygonaceae   |                   | Polygonum tinctorium          | [153]     |
| Santalales                    | Santalaceae    |                   | Thesium chinense              | [154]     |
|                               | Ebenaceae      |                   | Diospyros lotus               | [155]     |
|                               | Lecythidaceae  |                   | Planchonia grandis            | [156]     |
|                               | Myrsinoideae   |                   | Ardisia colorata              | [157]     |
|                               | Apocynaceae    |                   | Echites hirsuta               | [158]     |
|                               | Rubiaceae      |                   | Morinda citrifolia            | [159]     |
|                               |                |                   | Morinda morindoides           | [160]     |
| Vahliales                     | Vahliaaceae    |                   | Vahlia capensis               | [161]     |
### Table 1. Cont.

| Clade                  | Order          | Family            | Species           | Reference |
|------------------------|----------------|-------------------|-------------------|-----------|
| Mesangiosperms, Eudicots | Solanales      | Convolvulaceae    | Cuscuta australis | [162]     |
|                        |                |                   | Cuscuta chinensis | [163]     |
|                        | Solanales      |                   | Solanum nigrum    | [164]     |
|                        | Lamiales       | Oleaceae          | Chionanthus retusus | [165] |
|                        |                |                   | Olea europaea     | [166]     |
|                        | Lamiales       | Scrophulariaceae   | Buddleja indica Lam. | [167] |
|                        |                | Lamiaceae         | Origanum dictamnus | [168]     |
|                        |                |                   | Rosmarinus officinalis | [169] |
|                        | Apiales        | Apiaceae          | Bunium persicum   | [170]     |
|                        |                |                   | Bupleurum flavum  | [171]     |
|                        |                |                   | Bupleurum chinense | [172]     |
|                        | Asterales      | Asteraceae        | Heterotheca inuloides | [173] |
|                        |                |                   | Chromolaena moritziana | [174] |
|                        |                |                   | Ixeridium gracile  | [175]     |
|                        |                |                   | Lactuca scariola   | [176]     |
|                        |                |                   | Solidago virga-aurea | [177] |
|                        |                |                   | Helichrysum compactum | [178] |
|                        |                |                   | Europatorium perfoliatum L. | [179] |
|                        | Dipsacales     | Caprifoliaceae    | Sambucus nigra    | [181]     |
| Polypodiopsida, Moniliformopses | Polypodiales   | Dennstaedtiaceae  | Dennstaedtia scabra | [182] |
| Polypodiopsida, Ophioglossidae | Ophioglossales | Ophioglossaceae   | Ophioglossum petiolatum | [183] |

### Table 2. Kaempferol content of some common foodstuffs (fresh unless otherwise specified).

| Food             | Quantity (mg/kg) | Reference |
|------------------|------------------|-----------|
| Capers           | 2590             | [184]     |
| Saffron          | 2050             | [184]     |
| Onion leaves     | 832              | [185]     |
| Arugula          | 590              | [184]     |
| Kale             | 470              | [184]     |
| Brown mustard    | 380              | [184]     |
| Pumpkin          | 371              | [186]     |
| Ginger           | 340              | [184]     |
| Cauliflower      | 270              | [187]     |
| Common beans     | 260              | [184]     |
| Carrot           | 140              | [186]     |
| Black tea        | 118              | [186]     |
| Chive            | 100              | [184]     |
| Endive           | 100              | [184]     |
Table 2. Cont.

| Food                 | Quantity (mg/kg) | Reference |
|----------------------|------------------|-----------|
| Collard              | 90               | [184]     |
| Broccoli             | 80               | [184]     |
| Fennel leaves        | 70               | [184]     |
| Goji berry (dried)   | 60               | [184]     |
| Green chilli         | 39               | [186]     |
| Strawberry           | 5–8              | [188]     |

3. Kaempferol as an Antibacterial Agent

The antibacterial properties of the secondary metabolites of plants have been in the foreground of research in the last two decades [189–195]. Such research is even more important considering the emergence of numerous resistant [196,197] and multi-drug resistant (MRD) bacteria [198]. Kaempferol-containing extracts and preparations, as well as pure kaempferol compounds, have been tested as possible antibacterials for quite some time [121,144,199].

The investigation into the action mechanisms behind the antibacterial activity of kaempferol has proven difficult due to the large variety within the family of kaempferol derivatives but also due to the diversity in morphology and functions between the numerous species of bacteria. However, some theories have been advanced and validated regarding the potential action mechanisms in specific bacteria. For instance, [200] have shown that a mixture of kaempferol 3-O-b-(200-acetyl) galactopyranoside and quercetin exerts antibacterial effects through cell membrane disruption, followed by activation of apoptosis and DNA fragmentation in M. luteus cells. Kaempferol was also the most effective tested flavonoid in damaging the cell membrane of Escherichia coli in a study by [201], where the findings were objectified by showing bacterial protein leakage into the extracellular environment. Moreover, kaempferol and quercetin interact with 3-oxyacyl-[acyl carrier protein] reductase (FabG) and enoyl-acyl carrier protein reductase therefore inhibiting the biosynthesis of fatty acids by Mycobacterium, Pseudomonas aeruginosa, and Vibrio cholerae thus hindering the function of the cell envelope as well as the impeding creation of bacterial biofilms [202–204]. Another important antibacterial mechanism was demonstrated for E. coli, where kaempferol was shown to be the most effective flavonoid in directly inhibiting the bacterial DNA gyrase [205]; similarly, kaempferol inhibited the DNA gyrase in methicillin-resistant Staphylococcus aureus [206]. Kaempferol was also able to inhibit DNA helicases, more specifically SAPriA in Staphylococcus aureus, as shown by [207].

Actions of kaempferol compounds against Porphyromonas gingivalis, Prevotella intermedia, and Cutibacterium acnes have been described by [144,208]. The research of [209] had already indicated the antibacterial effect of the extract of S. hymettia against Enterobacter cloacae, and also other bacteria, as will be presented below. The extract of Helichrysum compactum, which contained pure kaempferol and also kaempferol-3-O-glucoside, proved to have a degree of antibacterial activity [178]. It is also possible, that the extract from Nephelium lappaceum, which contains pure kaempferol and also kaempferol-3-O-glucoside, proved to have a degree of antibacterial activity [178]. It is also possible, that the extract from Nephelium lappaceum, which contains pure kaempferol and also kaempferol-3-O-glucoside, proved to have a degree of antibacterial activity [178]. It is also possible, that the extract from Nephelium lappaceum, which contains pure kaempferol and also kaempferol-3-O-glucoside, proved to have a degree of antibacterial activity [178]. It is also possible, that the extract from Nephelium lappaceum, which contains pure kaempferol and also kaempferol-3-O-glucoside, proved to have a degree of antibacterial activity [178]. It is also possible, that the extract from Nephelium lappaceum, which contains pure kaempferol and also kaempferol-3-O-glucoside, proved to have a degree of antibacterial activity [178].
Subsequently, we will present the most important research on the antimicrobial activities of kaempferol against different bacterial genera (Table 3), which are human pathogens of particular interest.

| Genus   | Species                                      | Tested Substance                                      | MIC (µg/mL) | Year of Research | Reference |
|---------|----------------------------------------------|------------------------------------------------------|-------------|------------------|-----------|
| Gram-Negative Bacteria | Pure kaempferol-3,7-O-α-L-dirhamnoside | 8 | 2006 | [214] |
| Acinetobacter | A. baumannii | Extract from Kalanchoe fedtschenkoi | 128–256 | 2019 | [96] |
| | Artificial blend | n/a—no adm. of sole kaempferol | 2021 | [215] |
| | Extract from Geranium ibericum subsp. jubatum | 400 | 2021 | [132] |
| | Extracts from propolis | n/a—expressed as % of propolis | 2021 | [216] |
| Enterobacter | E. cloacae, E. aerogenes | Extract from Scabiosa hymettia | n/a (only inh. zone data) | 2008 | [209] |
| | | Extract from Labisa pumila Benth | Various depending on extract | 2011 | [211] |
| | Pure kaempferol-3,7-O-α-L-dirhamnoside | 2 | 2006 | [214] |
| | Extract from Scabiosa hymettia | n/a (only inh. zone data) | 2008 | [209] |
| | Extract from Labisa pumila Benth | Various depending on extract | 2011 | [211] |
| | Extract from Bupleurum chinense | n/a | 2020 | [172] |
| | Extracts from propolis | n/a—expressed as % of propolis | 2021 | [216] |
| Escherichia | E. coli | Conjugation of pure kaempferol with Ag nanoparticles | 62.5 | 2021 | [217] |
| | Extract from Rosa damascena Mill var. trigintipetala | n/a (only inh. zone data) | 2022 | [218] |
| | Extract from Yucca gigantea | 13.3 | 2022 | [219] |
| Klebsiella | K. pneumoniae | Pure kaempferol-3,7-O-α-L-dirhamnoside | 4 | 2006 | [214] |
| | Extract from Scabiosa hymettia | n/a (only inh. zone data) | 2008 | [209] |
| | Extract from Argyreia speciosa | 2 | 2009 | [220] |
| | Extract from Labisa pumila Benth | Various depending on extract | 2011 | [211] |
| | Extract from Bupleurum chinense | n/a | 2020 | [172] |
| | Extract from Geranium ibericum subsp. jubatum | 400 | 2021 | [132] |
| | Extract from Yucca gigantea | 12.5 | 2022 | [219] |
Table 3. Cont.

| Genus                  | Species                        | Tested Substance                          | MIC (µg/mL) | Year of Research | Reference |
|------------------------|--------------------------------|-------------------------------------------|-------------|------------------|-----------|
| Porphyromonas          | *P. gingivalis*                | Extract from *Syzygium aromaticum*        | 20          | 1996             | [144]     |
|                        |                                | Extract from *Syzygium aromaticum*        | 20          | 1996             | [144]     |
|                        |                                | Extract from *Uapaca heudelotti*          | 2           | 2020             | [212]     |
|                        |                                | Extract from *Geranium ibericum subsp. jubatum* | 300        | 2021             | [132]     |
|                        |                                | Extract from *Rosa damascena* Mill var. *trigintipetala* | n/a        | 2022             | [218]     |
|                        |                                | Extract from *Yucca gigantea*             | 14.8        | 2022             | [219]     |
|                        |                                | Extract from *Scabiosa hymettia*          | n/a (only inh. zone data) | 2008 | [209]     |
|                        |                                | Extract from *Labisa pumila* Benth        | n/a (only inh. zone data) | 2011 | [211]     |
|                        |                                | Extract from *Bryophyllum pinnatum* (Lank.) Oken | Various depending on extract | 2012 | [221]     |
|                        |                                | Extract from *Kalanchoe fedtschenkoi*     | 256         | 2019             | [96]      |
|                        |                                | Extract from *Bupleurum chinense*         | n/a         | 2020             | [172]     |
|                        |                                | Extract from *Yucca gigantea*             | 10.2        | 2022             | [219]     |
|                        |                                | Extract from *Bryophyllum pinnatum* (Lank.) Oken | Various depending on extract | 2012 | [221]     |
|                        |                                | Extract from *Uapaca heudelotti*          | 12.5        | 2020             | [212]     |
|                        |                                | Extract from *Yucca gigantea*             | 10.5        | 2022             | [219]     |
| Pseudomonas            | *P. aeruginosa*                | Extract from *Bryophyllum pinnatum* (Lank.) Oken | Various depending on extract | 2012 | [221]     |
|                        |                                | Extract from *Labisa pumila* Benth        | n/a         | 2011             | [211]     |
|                        |                                | Extract from *Scabiosa hymettia*          | n/a         | 2008             | [209]     |
|                        |                                | Extract from *Laurus nobilis*             | >256        | 2008             | [222]     |
|                        |                                | Extract from *Allium ursinum*             | 625         | 2009             | [224]     |
|                         |                                | Extract from *Mitracarpus scaber*         | 125         | 2000             | [223]     |
| Salmonella             | *S. typhi, S. typhimurium*     | Extract from *Bryophyllum pinnatum* (Lank.) Oken | Various depending on extract | 2012 | [221]     |
|                        |                                | Extract from *Labisa pumila* Benth        | n/a         | 2011             | [211]     |
|                        |                                | Extract from *Scabiosa hymettia*          | n/a (only inh. zone data) | 2008 | [209]     |
|                        |                                | Extract from *Laurus nobilis*             | >256        | 2008             | [222]     |
|                        |                                | Extract from *Allium ursinum*             | 625         | 2009             | [224]     |

**Gram-Positive Bacteria**

| Genus                  | Species                        | Tested Substance                          | MIC (µg/mL) | Year of Research | Reference |
|------------------------|--------------------------------|-------------------------------------------|-------------|------------------|-----------|
| Enterococcus           | *E. faecium, E. faecalis*     | Extract from *Combretum erythrophyllum*   | n/a         | 2004             | [140]     |
|                        |                                | Pure kaempferol-3,7-O-α-L-dirhamnoside    | 0.5         | 2006             | [214]     |
|                        |                                | Extract from *Laurus nobilis*             | >256        | 2008             | [222]     |
| Micrococcus            | *M. luteus*                    | Extract from *Labisa pumila* Benth        | Various depending on extract | 2011 | [211]     |
|                        |                                | Extract from *Mitracarpus scaber*         | 125         | 2000             | [223]     |
|                        |                                | Pure kaempferol-3,7-O-α-L-dirhamnoside    | 0.5         | 2006             | [214]     |
|                        |                                | Extract from *Laurus nobilis*             | >256        | 2008             | [222]     |
| Staphylococcus         | *S. aureus, S. epidermidis*    | Extract from *Combs ribes erythrophyllum* | n/a         | 2004             | [140]     |
|                        |                                | Pure kaempferol-3,7-O-α-L-dirhamnoside    | 0.5         | 2006             | [214]     |
|                        |                                | Extract from *Scabiosa hymettia*          | n/a (only inh. zone data) | 2008 | [209]     |
|                        |                                | Extract from *Laurus nobilis*             | >256        | 2008             | [222]     |
|                        |                                | Extract from *Allium ursinum*             | 625         | 2009             | [224]     |
| Genus            | Species                                  | Tested Substance                          | MIC (µg/mL)                      | Year of Research | Reference |
|------------------|------------------------------------------|-------------------------------------------|----------------------------------|------------------|-----------|
| Staphylococcus   | *S. aureus, S. epidermidis*              | Extract from *Platanus occidentalis*      | Various depending on the kaempferol compound | 2009             | [225]     |
|                  |                                          | Extract from *Laurus nobilis*             | Various depending on synergistic effects | 2009             | [206]     |
|                  |                                          | Extract from *Labisa pumila* Benth        | Various depending on extract      | 2011             | [211]     |
|                  |                                          | Extract from *Bryophyllum pinnatum* (Lank.) Oken | Various depending on extract      | 2012             | [221]     |
|                  |                                          | Extract from *Calliandra tergemina* (L.) Benth | Various depending on extract type and compound | 2014             | [226]     |
|                  |                                          | Extract from *Platanus occidentalis*      | n/a                              | 2015             | [227]     |
|                  |                                          | Extract from *Kalanchoe fedtschenkoi*     | 256                              | 2019             | [96]      |
|                  |                                          | Extract from *Platanus occidentalis*      | 16                               | 2020             | [228]     |
|                  |                                          | Extract from *Bupleurum chinense*         | n/a                              | 2020             | [172]     |
|                  |                                          | Extract from *Uapaca heudelotti*          | 12.5                             | 2020             | [212]     |
|                  |                                          | Conjugation of pure kaempferol with Ag nanoparticles | n/a—expressed as % of propolis | 2021             | [217]     |
|                  |                                          | Extract from propolis                     | n/a—expressed as % of propolis   | 2021             | [216]     |
|                  |                                          | Artificial blend with nanocrystals        | n/a—no adm. of sole kaempferol   | 2021             | [215]     |
|                  |                                          | Extract from *Yucca gigantea*             | 14.46                            | 2022             | [219]     |
| Streptococcus    | *S. pyogenes*                             | Extract from *Uapaca heudelotti*          | 6.25                             | 2020             | [212]     |
|                  |                                          | Pure kaempferol-3,7-O-α-L-dirhamnioside   | 8                                | 2006             | [214]     |
|                  |                                          | Extract from *Labisa pumila* Benth        | Various depending on extract      | 2011             | [211]     |
|                  |                                          | Extract from *Bupleurum chinense*         | n/a                              | 2020             | [172]     |
|                  |                                          | Extract from *Uapaca heudelotti*          | 6.25                             | 2020             | [212]     |
|                  |                                          | Extract from *Buddleja indica* Lam.       | 0.48                             | 2021             | [167]     |
|                  |                                          | Extract from *Astragalus creticus*         | n/a (expr. as inhibition %)      | 2021             | [100]     |
|                  |                                          | Conjugation of pure kaempferol with Ag nanoparticles | n/a                             | 2021             | [217]     |
|                  |                                          | Extract from *Rosa damascena* Mill var. *trigintipetala* | n/a (only inh. zone data) | 2022             | [218]     |
### Table 3. Cont.

| Genus          | Species                      | Tested Substance                        | MIC (µg/mL) | Year of Research | Reference     |
|---------------|------------------------------|-----------------------------------------|-------------|------------------|---------------|
| Cutibacterium | *C. acnes*                   | Extract from *Impatiens balsamina*     | 32–64       | 2007             | [208]         |
|               |                              | Extract from *Argyreia speciosa*       | 25          | 2009             | [220]         |
|               |                              | Extract from *Doliocarpus dentatus*    | 62.5        | 2017             | [229]         |
|               |                              | Extract from *Pluchea indica*          | n/a         | 2020             | [180]         |
|               |                              | Extract from *Bauhinia vahlii*         | n/a (expr. as inhibition %) | 2021 | [102]         |
|               |                              | Extract from *Vatairea macrocarpa*     | n/a         | 2021             | [230]         |

#### 3.1. Antibacterial Activity against *Acinetobacter baumannii*

This coccobacillus was once considered of low importance, from a medical standpoint, but has now emerged as a prominent healthcare unit-acquired and community-acquired infection. It frequently causes pulmonary infections and sepsis in immunocompromised patients [231]. Its antibiotic resistance and increased survival in harsh environments [232–234] further enhance its pathogenicity. At the moment, the results of the kaempferol-containing compounds against this pathogen are quite promising, and this can be important in the face of ever-increasing antibiotic resistance [96,215].

The compound kaempferol-3,7-O-α-L-dirhamnoside was found to be moderately inhibitory against *A. baumannii* [214]. A novel nanotechnology application involving a blend loaded with kaempferol nanocrystals showed very promising results against *A. baumannii* [215]; the research focused on treating infected wounds. Kaempferol-containing propolis extracts have also proved effective against *A. baumannii* in vitro [216]. The action of a further kaempferol-containing compound, the extract of *Geranium ibericum* subsp. *jubatum*, was also found to be almost as effective as some commercial antibiotics against this pathogen in vitro [132]. Earlier research [96] indicated that the kaempferol-containing extract of *K. fedtschenkoi* was effective against this pathogen.

#### 3.2. Antibacterial Activity against Bacillus Spp.

In general, the bacteria of this genus are aerobic ([235]; and references therein), rod-shaped bacteria [236], which are spore-forming and resistant to disinfectants and harsh environmental conditions [236,237]. According to [238], only a handful of species from this genus are pathogenic; although current research has focused on the antibacterial actions of kaempferol against *B. subtilis*, which is non-pathogenic, the existing research experience can be potentially used in the future to find effective antimicrobial phytochemicals against the pathogenic bacillus species, namely *B. anthracis* and *B. cereus* [239,240].

An extract of taif’s rose (*Rosa damascena* Mill. var. trigintipetala) exhibited antimicrobial activity against *B. subtilis* as well as other microorganisms. The extract contained kaempferol amongst other compounds [218]. Earlier research by [214] indicated that the antibacterial action of kaempferol-3,7-O-α-L-dirhamnoside, on its own, was quite moderate. The fermented aerial part of *Bupleurum chinense* also contains kaempferol and exhibited promising antibacterial action against this bacterium [172]. The compound kaempferol-3-O-glucoside, which was isolated from the stem bark of *Uapaca heudelotti*, was also effective in that regard [212].

Based on the research of [167], the kaempferol compounds of the extract of *Buddleja indica* Lam. enable it to act as a local antiseptic, effective against *B. subtilis*. The novel research of [100] on the extract of *Astragalus creticus*, which, among other compounds, contains kaempferol and kaempferol-7-O-β-D-glucopyranose, proved their efficacy against
this pathogen. Finally, the conjugation of kaempferol with silver nanoparticles proved effective against *B. subtilis* [217].

### 3.3. Antibacterial Activity against *Escherichia coli*

These bacteria are physiological colonizers of the gastrointestinal tract; the colonization begins typically shortly after birth. They typically do not cause disease in immunocompetent patients but will become pathogenetic, if they migrate to other locations or if their host becomes immunocompromised [241]. The most well-described *E. coli* pathogenic categories are the enteropathogenic *E. coli* (EPEC), the enterohaemorrhagic *E. coli* (EHEC), the enterotoxigenic *E. coli* (ETEC), the enteroaggregative *E. coli* (EAEC), the enteroinvasive *E. coli* (EIEC) and the diffusely adherent *E. coli* (DAEC) [242]. Commonly, *E. coli* infections are centered around the gastrointestinal and urogenital systems. Although most such infections can be easily treated, the emergence of multi-drug resistant (MDR) *E. coli* presents a novel therapeutical challenge [243].

The anti-microbial action of kaempferol-3,7-O-α-L-dirhamnoside was moderate against *E. coli* [214]. Success in that regard was also documented by [209] who used the extract of *S. hymettia*. The extract of *B. chinense*, which contained kaempferol-3-O-β-D-rutinoside and kaempferol proved effective against this bacterium [172]. The propolis extracts studied by [216] were also found to be effective against this pathogen. The combination of kaempferol with silver nanoparticles was also proven to be effective against *E. coli* [217]. The phytochemical extracts of [218,219] also proved effective against *E. coli*.

### 3.4. Antibacterial Activity against *Klebsiella pneumoniae*

*Klebsiella pneumoniae* represents an important human opportunistic pathogen and an emerging concern in clinical settings [244]. It accounts for virtually one-third of the total Gram-negative bacterial infections [245]. *Klebsiella* infections, especially in nosocomial settings, are rather severe [246]. The emergence of *K. pneumoniae* strains which are resistant to even last-line antibiotics [244,247] means that is not improbable, in the near future, that new compounds, whether natural or artificial, will be required to counter it. Interestingly, a strain of Klebsiella was found to even be resistant to chlorine treatment in water [248].

The anti-microbial action of kaempferol-3,7-O-α-L-dirhamnoside, was moderately effective against *K. pneumoniae* [214]. A similar anti-*Klebsiella* activity was also found by [172]. Earlier research by [220], on the extract of *Argyreia speciosa*, which was determined to contain kaempferol 7-O-methyl-3-sulphate, showed that it was inhibitory for *K. pneumoniae* growth. Similar successful antibacterial action was documented by [209], who used the extract of *S. hymettia*. The extract studied by [132] proved to also be effective against *K. pneumoniae*, as well as the extract studied by [219].

### 3.5. Antibacterial Activity against *Mycobacterium Spp.*

From the *Mycobacterium* genus, the most well-known and dangerous pathogen is *Mycobacterium tuberculosis*, which is the causative agent of tuberculosis, one of the oldest human diseases [249]. Although a vaccine against the disease exists, it is of varying efficiency [250] and has proven incapable of stopping the global epidemic [251]. While there exist antibiotics effective against tuberculosis during the last few years, the increase in antibiotic resistance of *M. tuberculosis* has led to the emergence of multi (MDR) [252], extensively (XDR), extremely (XXDR) and total (TDR) drug-resistant strains; these are estimated to kill about 75 · 10^6 people, in the next three decades [253]. Although resistance-conferring mutations may reduce the overall fitness of the bacteria, it has been suggested by [254–256] that the resistant bacteria may find ways to circumvent this limitation. Thus, it is evident that tuberculosis may again come to the foreground as a major disease, even in Western countries. *M. bovis* infects primarily cattle but can also spread to humans [257–260]; however, it is not of particular importance as a human pathogen [261]. Rather, its study is of interest in understanding the pathogenetic mechanism of *M. tuberculosis* [262].
Based on the research of [230], a leaf and hardwood extract from *Vatairea macrocarpa*, a plant used in Brazilian folk medicine, exhibited antibacterial action, in an in vivo model, in rat paws infected with *M. bovis*. The action of kaempferol-3-O-rhamnopyranoside was supplemented by that of other flavonoids in the extract. The extract was also found to have significant anti-inflammatory parameters.

The extract of *Argyreia speciosa* was found to have antibacterial properties against *M. tuberculosis* [220]. Another medicinal plant, *Doliocarpus dentatus*, proved to be effective in a rat model, as an antimycobacterial agent; the phenolic extract of its leaves contains kaempferol 3-O-α-L-rhamnopyranoside [229]. The extract of *Pluchea indica*, which contained kaempferol, was identified as a potent inhibitor of the *M. tuberculosis* CYP121 in a recent study by [180]. Finally, pure kaempferol from *Bauhinia vahlii*, was found, along with other flavonols, to be effective against *M. tuberculosis* [102].

3.6. Antibacterial Activity against *Pseudomonas aeruginosa*

This is a versatile opportunistic pathogen, from a metabolic point of view, which can cause both localized and systemic infections in humans, of varying degrees of severity [263]; recently, it has come to the foreground as a potent causative agent of nosocomial infections [264]. People already suffering from cystic fibrosis and COPD are at an increased risk of contracting *P. aeruginosa*, even outside of healthcare units [265–267]. It is of particular note that in cystic fibrosis patients, the bacterium may persist for decades [268]. Although some of the *P. aeruginosa* infections are relatively easily treated [269–271], other cases are still characterized by increased morbidity and mortality [267,272–274]. It has been observed that there is increasing resistance to antibiotics, of many *P. aeruginosa* strains, which is caused both by acquired and intrinsic mechanisms; this necessitates the development of new treatment avenues [275].

The research of [209], who tested the extract of *S. hymettia*, indicated that kaempferol-containing compounds were effective against *P. aeruginosa*. The extract of *Bryophyllum pinnatum* (Lank.) Oken also had some antibacterial activity against *P. aeruginosa* [221].

The extract prepared by [96] exhibited good antibacterial activity against *P. aeruginosa*. The extract of *Bupleurum chinense*, which has been already mentioned, proved effective against this pathogen [172]. The extract from *Yucca gigantea* also had an effect against *S. typhimurium* [219].

3.7. Antibacterial Activity against *Salmonella Spp.*

*Salmonella* is a common pathology in both developed and developing countries and represents a major public concern [276,277]; there are over 2600 recorded serotypes [278]. *Salmonellae* are foodborne pathogens, found mostly in poultry, eggs, and dairy products [279]. Recently, there has been an increase in the number of antibiotic-resistant strains; these are strains of increased virulence that are associated with increased mortality [280].

The extract of *Llapaca heudelotti* was effective, as an antimicrobial, against *S. typhi* [212]. Another effective antimicrobial against this pathogen is the extract of *Bryophyllum pinnatum* (Lank.) Oken [221]. The extract from *Yuca gigantea* also had an effect against *S. typhimurium* [219].

3.8. Antibacterial Activity against *Staphylococcus Spp.*

*Staphylococcus aureus* is a frequent human commensal and a common cause of various infections in humans. It can cause a wide variety of pathologies and associated symptoms, ranging from skin and soft tissue infections to infective endocarditis [281]; different staphylococcal strains are characterized by different aggressiveness properties [282]. The importance of *S. aureus* as a pathogen is further highlighted by the emergence of increasing antibiotic resistance [283,284]. The particular strain of *Staphylococcus aureus* which is resistant to methicillin is commonly referred to as MRSA (methicillin-resistant *Staphylococcus aureus*); it is a significant problem for health systems worldwide, both from a medical and a healthcare cost standpoint [285,286]. Its incidence rates present significant variations
depending on the countries and healthcare unit location but are nevertheless quite significant [287,288]. The situation is aggravated even more since different types of MRSA have been identified, namely the healthcare-associated MRSA (HA-MRSA), the community-associated MRSA (CA-MRSA), and the livestock-acquired MRSA (LA-MRSA) [289]. A rather more benign species is S. epidermidis, a commensal which is not a frequent cause of disease, but it is of increasing importance in nosocomial settings; in healthcare unit settings, its infection rates are approximately commensurate with those of S. aureus [290].

The early research of [214] indicated that kaempferol-3,7-O-α-l-dirhamnoside was particularly effective against S. aureus. The research of [209], on the extract of Scabiosa hymettia, which contained two kaempferol-based flavonoids, corroborated the antibacterial action of kaempferol and its derivatives, against S. aureus; it was also active against S. epidermidis. The extract of M. scaber, a plant used in traditional West African medicine, also proved effective against S. aureus [223]. It must be noted that in this last case, when the compounds of the extract were tested separately, kaempferol-3-O-rutinoside exhibited a low antibacterial action suggesting that either the antibacterial effects were attributable to other compounds or that it has some sort of synergistic action with the other compounds found in the extract. A degree of antibacterial activity, against S. aureus, was also exhibited by some of the extracts of Allium ursinum from Bulgaria [224]. The extract of Bryophyllum pinnatum (Lank.) Oken also exhibited interesting antibacterial properties against S. aureus [221].

The experiments of [222] determined that both kaempferol 3-O-α-L-(2″,4″-di-E-p-coumaroyl)-rhamnose (C2) and kaempferol 3-O-α-L-(2″-Z-p-coumaroyl-4″-E-p-coumaroyl)-rhamnose (C3), exerted a strong antibacterial activity against different MRSA strains in vitro. These compounds were extracted from Laurus nobilis, and were virtually ineffective against Streptococcus pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens. These same compounds were later found to have a synergistic effect with fluoroquinolones; namely, they increased the minimum inhibitory concentrations of these antibiotics. The same does not apply to hydrophobic quinolones [206].

Contemporary research [225], studying the anti-MRSA activities of the extract from Platanus occidentalis, determined that the numerous contained kaempferol compounds exhibited a satisfactory level of anti-MRSA activity. The research of [227], expounding upon the previous data, identified four isomers of kaempferol-3-O-α-L-(2″,3″-di-p-coumaroyl)-rhamnoside, from the same plant, which all exhibit anti-MRSA activity. It is possible that the main effect of such kaempferol-containing extracts is mostly attributable to the inhibition of the synthesis of the staphylococcal proteins, as determined by [228]. The earlier research of [226] also identified kaempferol-3-O-(2″,3″,4″-tri-O-galloyl)-α-L-rhamnopyranoside, along with other compounds, in the extract of Calliandra tergemina (L.) Benth. The anti-MRSA activity of the extract was verified experimentally.

The already mentioned research of [215] indicated that kaempferol, in the form of nanocrystals, was effective against multi-drug resistant (MDR) S. aureus. Two different propolis extracts, which contained kaempferol, also proved effective against S. aureus [216]. The earlier research of [96] also indicated the effectiveness of a kaempferol-containing extract, against S. aureus. Another extract, from the plant B. chinense also proved effective against S. aureus [172]; the results from the extract of Uapaca heudelotti against S. aureus were also positive [212]. The combination of kaempferol with Ag nanoparticles was also effective against this pathogen [217]. A successful result was also obtained by [219], who studied the effects of the extract of Y. gigantea; this extract was effective against S. epidermidis too.

3.9. Antibacterial Activity against Enterococci

In the last decades, enterococci have become a concern as nosocomial pathogens of note [291]; they have the potential to cause serious infections [292,293]. The most important pathogens of the genus are Enterococcus faecium and Enterococcus faecalis [294]. In particular, vancomycin-resistant enterococci (VRE) present a serious challenge because not only can they resist many antibiotics but they are quick to accrue further resistance [295].
Based on the research of [214], kaempferol-3,7-O-α[l]-dirhamnoside was quite effective against Enterococcus faecalis. The extract of Laurus nobilis, of [222], was also effective against VRE. The team of [140] isolated kaempferol, amongst other compounds, from the plant Combretum erythrophyllum and found that it was effective, as an antibacterial, against E. faecalis.

3.10. Antibacterial Activity against Proteus Spp.

Perhaps the most important representative of the infectious species of the genus Proteus is P. mirabilis, which causes infections of the urinary tract, such as cystitis and pyelonephritis; many cases of asymptomatic bacteriuria have been also documented, predominantly in elderly patients and individuals having type 2 diabetes [296,297]. Such infections are also associated with urinary stone formation and even become life-threatening [298]. P. vulgaris has also been implicated in resistant healthcare unit-acquired infections [299]. Proteus infections can lead to catheter obstruction in catheterized patients [300] and the urinary stones created may act as a focal point for further bacterial infections [301]; indeed, catheterization is perhaps the dominant risk factor in Proteus infections [302,303]. The bacteria of this genus are associated with numerous determinants of antibiotic resistance [304,305] and there is even a number of MDR Proteus strains [306–309]; the prevalence of such strains was recently estimated to be quite high, at least in certain settings [310].

The already-mentioned extract of [218] was effective against P. vulgaris. Of all the microorganisms tested in this study, P. vulgaris proved to be the most susceptible. On the other hand, Proteus mirabilis proved quite resistant to kaempferol-3,7-O-α[l]-dirhamnoside [214]. However, the extract studied by [132] was effective against this species, as well as the extract of Uapaca heudelotti [212]. This bacterial species proved also susceptible to the extract of Y. gigantea, which contains kaempferol-3-O-α-l-rhamnoside [219].

3.11. Antibacterial Activity against Vibrio cholerae

Cholera is most certainly an ancient disease of humans, although it has become a major health concern after the 19th century; it is a physiological inhabitant of aquatic ecosystems [311–313]. There is a number of pathogenic biotypes and there are several virulence factors [314]. The emergence of resistant strains of Vibrio cholerae has been documented in the past [315] and further resistance mechanisms continue to be observed [316].

Kaempferol and some of its derivatives were found to be effective against Vibrio cholerae, showing good antibacterial activity; in particular, kaempferol did not exhibit side effects such as toxicity to lymphocytes [140].

4. Antifungal Properties of Kaempferol

A very small number of fungi species are pathogenic to humans [317]; of these pathogenic fungi, some cause mild infections, while others, such as Candida spp. and Aspergillus spp., can even cause life-threatening, systemic infections [318]. Based on recent research, infections by Candida species, in hospital settings, represent an increasing health problem [319,320]. While fungi of this genus are generally benign, they can be the cause of oral candidiasis; in women, a significant percentage will suffer, sometime in their lives, from vaginal candidiasis [321,322]. Infections by Candida species are mostly determined by risk factors [323,324].

Likewise, Aspergillus fumigatus, while harmless to the immunocompetent host, will cause aspergillosis in immunocompromised patients; this represents an increasing concern with the number of such patients rising [325–328]. It is important to note that it is virtually impossible to evade exposure to this pathogen, as humans ingest hundreds of its conidia on a daily basis [329–331]. Another important aspect of A. fumigatus infections is that they may occur in the cavities left over in patients who have recovered from tuberculosis [332,333]; this is interesting, considering that kaempferol is known to be effective against M. tuberculosis, as already discussed. Therefore, for this specific case, a kaempferol-
containing agent could both suppress the initial infection and act preventatively against possible aspergillosis.

Finally, Cryptococcus neoformans is one of the deadliest fungal pathogens [334] and, according to a recent survey kills thousands of infected patients each year [335]. Its importance as a disease of global interest was realized after the 1970s [336,337]. Several risk factors are associated with an increased risk of cryptococcosis infection [338]; for example, as happens with other pathogens, cryptococcosis is particularly dangerous for HIV/AIDS patients [339]. In general, despite the availability of antifungal drugs, there is an emerging resistance as the microorganisms adapt [340]; coupled with the known side effects of many antifungal drugs [341], the importance of the development of novel therapeutic strategies, based on natural compounds becomes all the more obvious.

Probably the first antifungal action of a kaempferol-containing compound was documented by [223], who tested the extract of Mitracarpus scaber, a plant used in traditional West African medicine. Both isolated kaempferol-3-O-[3-O-acetyl-6-O-(E)-p-coumaroyl]-β-D-glucopyranoside and kaempferol 3-O-b-D-kaempferol 3-O-b-D-glucopyranoside, from S. hymettia, were found to be active in vitro against C. albicans, C. glabrata and C. tropicalis [209]. As mentioned above, the kaempferol compound of the extract was not as effective when tested in isolated form. Moderate antifungal activity, against C. albicans was exhibited by some kaempferol-containing extracts from Allium ursinum [224]. The extract from Labisa pumila Benth, discussed before, also has a quite notable antifungal effect [211]. The extract from Bryophyllum pinnatum (Lank.) Oken exhibited interesting antifungal activity against C. albicans, C. parapsilosis and also Cryptococcus neoformans [221].

A comparatively weak inhibitory activity, at maximum concentration, was exhibited by kaempferol-3-O-(6’-galloyl)-β-D-glucopyranoside, isolated from Basconema acuminatum [342]. Pure kaempferol also proved very effective against C. albicans both in vitro and in vivo in mice [343]. A possible effect against fungi of the Candida spp. was reported for the extract of Trachyspermum ammi, which contained kaempferol-(coumaroyl glucosyl)-rhamnoside [344]. The extract from Y. gigantea had a definite antifungal effect [219]. In the recent research of [345], it was determined, based on binding mechanisms, that kaempferol, at least when contained in an extract, may have a significant fungicidal effect in cases of vaginal candidiasis.

The antifungal activity of kaempferol was also proven by the research of [132]. The extract prepared by [218], which also contained many other phytochemicals, had antifungal activity against Candida albicans and Aspergillus fumigatus. Moreover, significant fungistatic activity was exhibited by the bark extract of Spondias mombin [213]. A summary of the research on the antifungal properties of kaempferol mentioned in the text is presented in Table 4.

Table 4. Kaempferol-containing extracts and compounds with a verified antifungal potential.

| Genus   | Species                | Tested Substance                      | MIC (µg/mL) | Year of Research | Reference |
|---------|------------------------|---------------------------------------|-------------|-----------------|-----------|
| Aspergillus | A. fumigatus        | Extract from Rosa damascena Mill var. trigintipetala | n/a (only inh. zone data) | 2022 | [218] |
|         |                        | Extract from Mitracarpus scaber       | 250–500     | 2000            | [223]   |
|         |                        | Pure kaempferol-3-O-(6’-galloyl)-β-D-glucopyranoside | 200         | 2004            | [342]   |
| Candida | C. albicans, C. tropicalis, C. glabrata | Extract from Scabiosa hymettia | n/a (only inh. zone data) | 2008 | [209] |
|         |                        | Pure kaempferol                       | 25          | 2008            | [343]   |
|         |                        | Extract from Allium ursinum           | >625        | 2009            | [224]   |
|         |                        | Extract from Labisa pumila Benth      | Various depending on extract       | 2011 | [211] |
|         |                        | Extract from Bryophyllum pinnatum (Lank.) Oken | Various depending on extract       | 2012 | [221] |
### Table 4. Cont.

| Genus         | Species Tested | Tested Substance                                       | MIC (µg/mL) | Year of Research | Reference |
|---------------|----------------|--------------------------------------------------------|-------------|------------------|-----------|
| Candida       | *C. albicans*, *C. tropicalis*, *C. glabrata* | Extract from *Geranium ibericum* subsp. *jubatum* | 400         | 2021             | [132]     |
|               |                | Extract from *Rosa damascena* Mill var. *trigintipetala* | n/a (only inh. zone data) | 2022 | [218] |
|               |                | Bark extract from *Spondias mombin*                    | n/a         | 2022             | [213]     |
| Cryptococcus  | *C. neoformans* | Extract from *Bryophyllum pinnatum* (Lank.) Oken       | Various depending on extract | 2012 | [221] |

#### 5. Antiprotozoal Properties of Kaempferol

Plant extracts containing kaempferol have shown antiprotozoal activity based on a number of researches against some of the most common protozoal pathogens (Table 5). In this section, we will review the most prominent research and list the plants identified as possible sources of cure and prevention (Table 6).

### Table 5. Protozoal diseases discussed in the text and their causative agents.

| Disease                  | Causative Agents                          | Endemic Areas                                      | References |
|--------------------------|-------------------------------------------|----------------------------------------------------|------------|
| Amoebiasis               | *Entamoeba histolytica*                   | Central and South America, Africa, India           | [346,347] |
| Giardiasis               | *Giardia lamblia*                         | Worldwide                                           | [348,349] |
| Human African trypanosomiasis | *Trypanosoma brucei gambiense*, *Trypanosoma brucei rhodensiense*, *Trypanosoma brucei brucei*, *Trypanosoma congolense*, *Trypanosoma evansi* | Sub-Saharan (Central and West Africa)               | [350]     |
| Malaria                  | *Plasmodium vivax*, *Plasmodium ovale*, *Plasmodium knowlesi* | South America, Africa, India, and South Pacific islands | [351,352] |
| Leishmaniasis            | *Leishmania donovani*, *Leishmania major*, *Leishmania mexicana*, *Leishmania tropica*, etc. | Africa, Central and South Asia, Central and South America | [353–355] |

### Table 6. Antiprotozoal activity of kaempferol compounds based on current research.

| Active Kaempferol Compound | Extracted from | Active against | IC50 (µg/mL) | Year of Study | References |
|----------------------------|----------------|----------------|--------------|---------------|------------|
| Kaempferol                 | HELIANTHEMUM  | E. histolytica | 9.7          | 1995          | [136]     |
| Kaempferol                 | HELIANTHEMUM  | E. histolytica, G. lamblia | 7.93, 8.73 | 1998          | [356]     |
| Kaempferol                 | HELIANTHEMUM  | E. histolytica, G. lamblia | 7.93, 8.73 | 1999          | [357]     |
| Kaempferol                 | HELIANTHEMUM  | E. histolytica, G. lamblia | 7.93, 8.73 | 1999          | [358]     |
| Kaempferol-7-methylether   | Alomia myriadenia | T. cruzi | n/a (expressed as % of T. cruzi lysis) | 7.9–8.3 | 2003          | [359] |
| Kaempferol                 | Cuphea pinetorum | E. histolytica, G. lamblia | Various depending on kaempferol compound | 2006 | [160] |
| Kaempferol                 | Morinda morindoides | E. histolytica | n/a (expressed in µM) | 2006 | [361] |
| Kaempferol-3-O-α-L-arabinopyranosyl (1→2)-α-L-rhamnopyranoside | Kalanchoe pinnata | Leishmania spp. | >100 | 2006 | [360] |
| 8-(1:1)-DMA-kaempferide    | Pure compound | P. falciparum | n/a (expressed in µM) | 2006 | [361] |
Table 6. Cont.

| Active Kaempferol Compound | Extracted from | Active against | IC50 (µg/mL) | Year of Study | References |
|----------------------------|----------------|----------------|--------------|--------------|------------|
| Kaempferol                 | Eupatorium perfoliatum L. | P. falciparum | 2.7 (whole extract) | 2011 | [179] |
| Kaempferol                 | Cayratia trifolia Linn | Trypanosoma spp. | n/a | 2011 | [98] |
| Kaempferol rhamnosides and glycosides | Pure compounds | Plasmodium spp. | n/a (expressed in µM) | 2016 | [362] |
| Kaempferol                 | Annona cherimola Miller | E. histolytica, G. lamblia | 7.9, 8.7 | 2017 | [85] |
| Kaempferol-3,7-dimethylether | Cnidoscolus chayamansa | E. histolytica, G. lamblia | ≤27.43 | 2017 | [363] |
| Kaempferol-3,7-di-O-methylether | Solanum paludosum Moric | L. amazonensis | n/a (expressed in µM) | 2019 | [364] |
| Kaempferol, 4′-methoxykaempferol, 4′,7-dimethoxykaempferol | Propolis | T. brucei, L. mexicana | n/a (expressed in µM) | 2021 | [365] |
| 3-O-a-L-rhamnoside, and other kaempferol compounds | Lotus corniculatus L. | Trypanosoma spp., Plasmodium spp. | 0.98, 1.57 | 2021 | [366] |

5.1. Antiprotozoal Action against Entamoeba histolytica and Giardia lamblia

Probably the first description of an antiprotozoal activity of a kaempferol-containing extract was made by [136] who studied the extract of Helianthemum glomeratum against Entamoeba histolytica in vitro, with successful results. Shortly after, kaempferol was also isolated from the roots of Cuphea pinetorum; it too was effective against E. histolytica and Giardia lamblia [356,357] in vitro. The importance of kaempferol in the antiprotozoal activity of these extracts was verified by [141]. The antiprotozoal activity of H. glomeratum, and the importance of kaempferol, were also examined by [358]. These plants are used in Mayan traditional medicine. The same promising results against E. histolytica were obtained when using the extract of Morinda morindoides [160]. The potency of kaempferol against E. histolytica was also demonstrated by [85]. Against both E. histolytica and G. lamblia, kaempferol-3,7-dimethylether was shown to have a degree of antiprotozoal activity in vitro [363]. This antiprotozoal activity of kaempferol against E. histolytica is important in the wider context of the activity of numerous flavonoids against this parasite [367]; such natural compounds may enable the development of new drugs against resistant parasites.

5.2. Antiprotozoal Action against Trypanosoma Spp.

This disease, also known as the sleeping sickness, is caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense. It is a disease endemic to African countries [368]. It is mainly transmitted by flies of the genus Glossina, although transmission by other blood-sucking insects has also been documented [369,370]; it has even been proposed that due to the different possibilities of transmission, there may be outbreaks of this disease in non-endemic areas [371]. The treatment of this disease is based on a few drugs, which can be divided into two groups, the blood–brain barrier-crossing drugs (melarsoprol, eflornithine, nifurtimox) and the non-blood–brain barrier-crossing drugs (pentamidine, suramin) [372]. While currently there is a decrease in human African trypanosomiasis cases [373]. At the moment, resistance to treatment is not a massive issue for this particular disease, although resistant cases have been clinically reported [374]; furthermore, effective treatment options are required for the final stages of the disease [374].

Kaempferol-7-methylether was one of the compounds identified in the extract of Alomia myriadenia which was very effective against Trypanosoma cruzi in vitro [359]. On the other hand, the kaempferol-containing extract of Conyza filaginoides, was not found...
to be effective against *Trypanosoma* spp. and *Giardia* spp. [375]. Possibly, kaempferol is also important in the antiprotozoal activity exhibited by the bark extract of *Cayratia trifolia* Linn [98]. Contrary to that, the results of [376] were disappointing in that regard. Another research, focusing on kaempferol-3-O-methylether-5-O-β-D-glucoside and kaempferol-8-hydroxy-3,7-O-dimethylether-5-O-β-D-glucoside, from the extract of the plant *Zanthoxylum pistaciifolium* Griseb. found that they had no significant activity against either *T. cruzi* or *T. brucei* [377]. The compound 4′-methoxykaempferol, isolated from the extract of temperate propolis, proved to be quite effective against *T. brucei* [365]. The extract of *Lotus corniculatus* L. was found to be effective against *Trypanosoma* spp. [366].

5.3. Antiprotozoal Action against *Plasmodium* Spp.

Malaria is a well-known disease since ancient times and is caused by the amoeboïd intracellular parasite *Plasmodium*; five of the 172 *Plasmodium* species are infectious to humans (*P. malariae*, *P. falciparum*, *P. vivax*, *P. ovale*, *P. knowlesi*); others are rarely infectious [378–380]. Regardless, their morphology and biology are quite similar [381]. The transmission of malaria is performed through its vectors, the female mosquitoes of the genus *Anopheles* [382]; subsequently, the parasite will infect first the hepatocytes and then the erythrocytes [383]. Currently, the most widespread therapy against malaria is the use of artemisinin and artemisinin-based combination therapy (ACT) [384]. In addition, there is an emerging resistance to antimalarial drugs, which threatens future efforts to eliminate the disease [385]. While endemic malaria is a major health concern, it may even be a health hazard in non-endemic countries [386].

Interestingly, 8-(1;1)-DMA-kaempferide, a flavonoid very similar to kaempferol [387], was found to have an antiprotozoal potential against *Plasmodium falciparum* [361]. Based on the research of [179], the extract of *Eupatorium perfoliatum* L. exhibited an in vitro antiprotozoal activity against *P. falciparum*; the extract contained kaempferol but the dimeric guaianolide was shown to be the most important part of the antiprotozoal activity. Some kaempferol metabolites proved to be effective against the malaria parasite when isolated in vitro [362]. The inability of kaempferol to influence negatively the formation of hemozoin, lead [388] to suggest that the in vitro antiplasmodial activity of kaempferol must not be related to any heme-binding activity pathway. The aforementioned study of [377], found two kaempferol glycosides to be ineffective against *P. falciparum*. Finally, the extract of *Lotus corniculatus* L., which contains pure kaempferol alongside some other kaempferol compounds has antiprotozoal activity against *Plasmodium* spp. [366].

5.4. Antiprotozoal Action against *Leishmania* Spp.

Leishmaniasis is a tropical and subtropical disease, mainly transmitted to humans through the sand flies of the genuses *Phlebotomus* and *Lutzomyia* [389]. The disease is extremely dangerous and presents a variety of symptoms; occasionally it can be fatal [390]. There exist over 20 species of the *Leishmania* parasite which can infect humans; leishmaniasis is a zoonosis and can be divided into visceral, cutaneous, and mucocutaneous [391]. The traditional treatment for leishmaniasis is based on antimonials, against which there is, however, increasing resistance [392]; antimonials also have frequent and rather severe side effects [393,394].

Compounds from the extract of *K. pinatta* were found to have antileishmanial activity [360]. In an in vitro assay, kaempferol-3,7-di-O-methylether was found to be able to induce cell death in *Leishmania amazonensis* [364]. When isolated from temperate propolis, 4′,7-dimethoxykaempferol was found to be quite effective against *L. amazonensis* in vitro [365].

6. Kaempferol-Containing Plants in Traditional Medical Systems

As mentioned elsewhere in this paper, a number of plants that contain kaempferol compounds are included in many traditional medical systems, all around the world. It is interesting to note that their traditional applications frequently correspond with their current effects under research. In this section, we will group the most important such
plants, and their applications mentioned in this paper (Table 7), and then briefly examine the importance of some kaempferol-containing plants in the context of traditional Chinese medicine.

Table 7. Correlation between ethnobotanical and described uses of certain kaempferol-containing plants.

| Plant                               | Traditional/Ethnobotanical Uses                                      | Uses Described in This Paper                                      | References |
|-------------------------------------|---------------------------------------------------------------------|------------------------------------------------------------------|------------|
| Annona cherimola Miller            | Traditional Mexican medicine                                        | Antiprotozoal (against *E. histolytica*, *G. lamblia*)           | [85,395,396]|
| Argyreia speciosa                  | Traditional Indian medicine                                         | Antibacterial (against *K. pneumoniae*, *M. tuberculosis*)        | [220,397,398]|
| Astragalus ceticus                 | Traditional Chinese medicine, traditional Pakistani medicine       | Antibacterial (against *B. subtilis*)                           | [100,399]  |
| Bauhinia vahlii                    | Traditional Indian medicine                                         | Antibacterial (against *M. tuberculosis*)                        | [102,400,401]|
| Bryophyllum pinatum                | Traditional medical systems of tropical Africa and America,        | Antibacterial (against *P. aeruginosa*, *S. aureus*, *S. typhi*); | [221,402,403]|
| Buddleja indica Lam                | Traditional African medicine                                       | Antibacterial (against *B. subtilis*); Antibacterial (against *B. subtilis*, *E. coli*, *K. pneumoniae*, *P. aeruginosa*, *S. aureus*) | [167,404]  |
| Bupleurum chinense                 | Traditional Chinese medicine                                       | Antibacterial (against *B. subtilis*; *B. subtilis*, *E. coli*, *K. pneumoniae*) | [172,405,406]|
| Cnidoscolus chayamansa             | Traditional Mexican medicine                                        | Antiprotozoal (against *E. histolytica*, *G. lamblia*)           | [363,407]  |
| Cuphea pinetorum                   | Traditional Mayan medicine                                          | Antiprotozoal (against *E. histolytica*, *G. lamblia*)           | [141,408]  |
| Doliocarpus dentatus               | Traditional Brazilian medicine, traditional Peruvian medicine       | Antibacterial (against *M. tuberculosis*)                        | [229,409]  |
| Geranium ibericum jubaturn         | Ethnobotanical usage in Malaya, Eastern Anatolia                   | Antibacterial (against *A. baumannii*, *K. pneumoniae*)          | [132,410]  |
| Helianthemum glomeratum            | Traditional Mayan medicine                                          | Antiprotozoal (against *E. histolytica*, *G. lamblia*)           | [358,411]  |
| Impatiens balsamina                | Traditional Chinese medicine and traditional medicinal systems of  | Antibacterial (against *P. acnes*)                              | [208,412,413]|
| Kalanchoe fedtschenkoi             | Traditional Chinese medicine, traditional Chinese medicine,        | Antibacterial (against *A. baumannii*, *P. aeruginosa*, *S. aureus*) | [96,414] |
|                                    | traditional Brazilian medicine, Traditional African medicine       |                                                                   |            |
| Labisia pumila Benth               | Traditional Malayan medicine                                       | Antibacterial (against *B. cereus*, *B. subtilis*, *E. aerogenes*, *E. coli*, *K. pneumoniae*, *M. luteus*, *P. aeruginosa*, *S. aureus*); antifungal (against *C. albicans*) | [211,415,416]|
| Lotus corniculatus L.              | Traditional Turkish medicine, traditional Russian medicine,        | Antiprotozoal (against *Trypanosoma spp.*)                       | [366,417,418]|
|                                    | traditional Egyptian medicine                                       |                                                                   |            |
| Mitracarpus scaber                 | Traditional Malian medicine                                         | Antibacterial (against *S. aureus*; antifungal (against *A. fumigatus*) | [223,419]  |
| Morinda morindoides               | Various traditional African medical systems                         | Antiprotozoal (against *E. histolytica*)                         | [160,420,421]|
| Pluchea indica                     | Traditional Thai medicine, traditional Indian medicine             | Antibacterial (against *M. tuberculosis*)                        | [180,422,423]|
| Propolis                           | Ancient Greek medicine, Ancient Roman medicine, Ancient Egyptian   | Antibacterial (against *A. baumannii*, *E. coli*, *S. aureus*);  | [216,365,424]|
|                                    | medical systems                                                    | antiprotozoan (against *T. brucei, L. mexicana*)                |            |
| Rosa damascena Mill var. trignitipectala | Ancient Persian medicine, traditional Arab medicine, traditional | Antibacterial (against *B. subtilis*, *E. coli*, *P. vulgaris*); antifungal (A. fumigatus, *C. albicans*) | [218,425–428]|

[366,417,418, 160,420,421]
Table 7. Cont.

| Plant                          | Traditional/Ethnobotanical Uses                                         | Uses Described in This Paper                                                                 | References            |
|--------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------|
| *Scabiosa hymettia*            | Traditional Greek medicine                                             | Antibacterial (against *E. coli*, *K. pneumoniae*, *P. aeruginosa*, *S. aureus*, *S. epidermidis*, *E. cloacae*); antifungal (C. albicans, C. glabrata, C. tropicalis) | [209,429]             |
| *Solanum paludosum*           | South American folk medicine                                           | Antiprotozoal (against *L. amazonensis*)                                                       | [364,430]             |
| *Syzygium aromaticum*          | Various traditional medicinal systems of Asia                          | Antibacterial (against *P. gingivalis*, *P. intermedia*)                                       | [144,431]             |
| *Uapaca heudelotii*            | Traditional Congolese medicine, various other local African medical traditions | Antibacterial (against *S. pneumoniae*, *S. aureus*, *S. typhi*, *P. mirabilis*, *B. subtilis*) | [212,432,433]         |
| *Uapaca heudelotti*            | Traditional African medicine                                           | Antibacterial (against *B. subtilis*, *S. aureus*, *S. pneumoniae*, *S. typhi*)                 | [212,433]             |
| *Vatairea macrocarpa* (Benth)  | Traditional Brazilian medicine                                         | Antibacterial (against *M. bovis*)                                                             | [230,434]             |
| *Yucca gigantea*               | Native American medicine, traditional Guatemalan medicine              | Antibacterial (against *E. coli*, *K. pneumoniae*, *P. aeruginosa*, *S. aureus*, *S. epidermidis*, *S. typhimurium*, *P. mirabilis*) | [219,435,436]         |

*Kaempferol-Containing Plants in the Context of Traditional Chinese Medicine*

Herbal medicine is still regarded as an integral part of Traditional Chinese Medicine [437], and continues to be relevant in all parts of the world. As has been already proven, the study of these ancient practices can lead to novel therapies and drug discovery [438].

The use of the flower of the clove, known as dingxiang, is indicated to counteract the invasion of cold, and also to warm the kidneys; associated clinical signs include vomiting, hiccup, diarrhea, impotence, and leg weakness [439].

*Bupleurum chinense*, also known as *radix bupleuri*, or chaixu, is used in a variety of herbal formulas, which are associated with harmonizing lesser yang-stage disorders; some formulas, are also used against malaria. Other formulas, containing *B. chinense* are used to release exterior wind and heat [440]. To be more precise, *radix bupleuri* is derived from the roots of *B. chinense* [441]. Modern phytochemical research indicates that it has a wide range of pharmacological effects [442–447].

Geranium is also used in Traditional Chinese Medicine, both in anti-inflammatory and anti-microorganism applications [448]; current research has verified its anti-inflammatory potential [449].

*Astragalus creticus* is a plant that is endemic both to Greece and China [450]; it is used, either alone or in herbal formulas to warm the meridians and dispel cold [440]. In warming the meridians, it is ideal for rectifying the deficiency of the lung, spleen, and stomach meridians [439]. In Western Medicine terminology, it is used in cases of body weakness, as a diuretic, against digestive system disorders, or simply as a food supplement [451]. This is one of the most widespread plant genuses, and it has numerous ethnobotanical applications [452–458]. It would be interesting to compare the similarities between the applications of these plants in different medical systems.

Lastly, propolis, which is a bee product containing plant elements, not a plant per se, is an integral compound of many medicinal systems. It is used in traditional Chinese medicine, for its anti-inflammatory properties [459] and also has an anti-diabetic potential [460].

7. Discussion and Conclusions

In recent years, the field of phytochemistry has been rapidly developing with the aim of developing new drugs based on plant-derived compounds. At the same time, the field of ethnopharmacology studies the use of traditional medicinal plants of different regions and their possible applications in modern medical and pharmacological practice. Such approaches are integrated into the innovative practices which constitute the driving force behind the development of new therapeutical approaches [461].
As discussed in this paper, plants that contain kaempferol and its associated compounds have been tested for a number of effects, from anticarcinogenic to antibacterial, antifungal, and antiprotozoal. Indeed, the identification of natural compounds with anticarcinogenic potential has been a mainstay of medical research in the last decades [462]. Applications of such products have been proposed by [463] and the related new perspectives in drug discovery of many such natural agents have been summarized by [464].

Regarding the focus of this paper, in light of the promising effects of kaempferol compounds in the field of clinical microbiology, it can be said with a degree of certainty that it represents a novel potential for drug design. This is all the more important given the emerging resistance of many pathogens to traditional drugs. We may further postulate that given the wide range of kaempferol effects, drugs that may combat more than one condition may be developed; for example, using kaempferol as the basic agent, infections in cancer patients may be treated, combatting the pathogen and the cancer cells at the same time. This is a subject for future research.

Finally, as presented in the last part of the paper, kaempferol-containing plants are found in the traditional medicinal systems of almost every region; this attests to the efficacy of such treatments. In the particular case of traditional Chinese medicine, more often than not, such plants are used in conjunction with other plants and herbs, in herbal formulas. We propose, from a future research perspective, that these formulas should be tested, initially in vitro, to ascertain the relative efficacy of their components, and whether the kaempferol compounds of the ingredients can exert their actions on their own or in tandem with some of the other contained compounds.

Author Contributions: Conceptualization, A.P., K.P., C.S. and C.C.; resources, I.A.B., E.M.P., D.C.P. and A.C.; writing—original draft preparation, A.P., K.P., I.A.B., E.M.P., D.C.P., A.C., R.S.C., C.S., C.C. and D.O.C.; writing—review and editing, A.P., K.P., A.C., C.S., C.C. and D.O.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Veeresham, C. Natural products derived from plants as a source of drugs. *J. Adv. Pharm. Technol. Res.* 2012, 3, 200–201. [CrossRef] [PubMed]
2. Katiyar, C.; Gupta, A.; Kanjilal, S.; Katiyar, S. Drug discovery from plant sources: An integrated approach. *Ayu* 2012, 33, 10–19. [CrossRef] [PubMed]
3. Seidel, V. Plant-Derived Chemicals: A Source of Inspiration for New Drugs. *Plants* 2020, 9, 1562. [CrossRef] [PubMed]
4. Petran, M.; Dragos, D.; Gilca, M. Historical ethnobotanical review of medicinal plants used to treat children diseases in Romania (1860s–1970s). *J. Ethnobiol. Ethnomedicine* 2020, 16, 15. [CrossRef] [PubMed]
5. Verma, A.R.; Vijayakumar, M.; Mathela, C.S.; Rao, C.V. In vitro and in vivo antioxidant properties of different fractions of Moringa oleifera leaves. *Food Chem. Toxicol.* 2009, 47, 2196–2201. [CrossRef] [PubMed]
6. Gilca, M.; Gaman, L.; Panait, E.; Stoian, I.; Atanasiu, V. Chelidonium majus—an integrative review: Traditional knowledge versus modern findings. *Complement. Med. Res.* 2010, 17, 241–248. [CrossRef] [PubMed]
7. Singh, N.; Bhalla, M.; de Jager, P.; Gilca, M. An overview on ashwagandha: A Rasayana (rejuvenator) of Ayurveda. *Afr. J. Tradit. Complement. Altern. Med.* 2011, 8, 208–213. [CrossRef]
8. Singh, N.; Pandey, B.; Verma, P.; Bhalla, M.; Gilca, M. Phyto-pharmacotherapeutics of Cyperus rotundus Linn.(Motha): An overview. *Indian J. Nat. Prod. Res.* 2012, 3, 467–476.
9. Liu, R.H. Health-promoting components of fruits and vegetables in the diet. *Adv. Nutr.* 2013, 4, 384s–392s. [CrossRef] [PubMed]
10. Reedy, J.; Krebs-Smith, S.M.; Miller, P.E.; Liese, A.D.; Kahle, L.L.; Park, Y.; Subar, A.F. Higher Diet Quality Is Associated with Decreased Risk of All-Cause, Cardiovascular Disease, and Cancer Mortality among Older Adults. *J. Nutr.* 2014, 144, 881–889. [CrossRef] [PubMed]
38. De Lira Mota, K.S.; Dias, G.E.N.; Pinto, M.E.F.; Luiz-Ferreira, Â.; Monteiro Souza-Brito, A.R.; Hiruma-Lima, C.A.; Barbosa-Filho, J.M.; Batista, L.M. Flavonoids with Gastroprotective Activity. *Molecules* **2009**, *14*, 979–1012. [CrossRef]

39. Antonisamy, P.; Subash-Babu, P.; Albert-Baskar, A.; Alshatwi, A.A.; Aravindhan, A.; Ignacimuthu, S.; Choi, K.C.; Lee, S.C.; Kim, J.-H. Experimental study on gastroprotective efficacy and mechanisms of luteolin-7-O-glucoside isolated from Ophiirrhiza mungos Linn. in different experimental models. *J. Funct. Foods* **2016**, *25*, 302–313. [CrossRef]

40. Nwankwo, J.O.; Tahhteng, J.G.; Emerole, G.O. Inhibition of aflatoxin B1 genotoxicity in human liver-derived HepG2 cells by kolaviron biflavonoids and molecular mechanisms of action. *Eur. J. Cancer Prev.* **2000**, *9*, 351–361. [CrossRef]

41. Snijman, P.W.; Swaneveelder, S.; Joubert, E.; Green, I.R.; Gelderblom, W.C.A. The antimutagenic activity of the major flavonoids of rooibos (Aspalathus linearis). Some dose–response effects on mutagen activation–flavonoid interactions. *Mutat. Res. Genet. Toxicol. Environ. Mutagen.* **2007**, *631*, 111–123. [CrossRef]

42. Carvalho-Silva, L.B.D.; Dionisio, A.P.; Pereira, A.C.D.S.; Wurlitzer, N.J.; Brito, E.S.D.; Bataglione, G.A.; Brasil, I.M.; Eberlin, M.N.; Liu, R.H. Anti-inflammatory, antimutagenic and antioxidant activities of a Brazilian tropical fruit juice. *LWT—Food Sci. Technol.* **2014**, *59*, 1319–1324. [CrossRef]

43. Serpeloni, J.M.; Leal Specian, A.F.; Ribeiro, D.L.; Tuttis, K.; Vilegas, W.; Martínez-López, W.; Dokkedal, A.L.; Saldanha, L.L.; de Syllós Cólus, I.M.; Varanda, E.A. Antimutagenicity and induction of antioxidant defense by flavonoid rich extract of Myrcia bella Cambess. in normal and tumor gastric cells. *J. Ethnopharmacol.* **2015**, *176*, 345–355. [CrossRef]

44. Zarev, Y.; Foubert, K.; Lucia de Almeida, V.; Anthonissen, R.; Elgorashi, E.; Apers, S.; Ionkova, I.; Verschaeve, L.; Pieters, L. Antigenotoxic prenylated flavonoids from stem bark of Erythrina latissima. *Phytochemistry* **2017**, *141*, 140–146. [CrossRef]

45. Neuhouser, M.L. Dietary flavonoids and cancer risk: Evidence from human population studies. *Nutr. Cancer* **2004**, *50*, 1–7. [CrossRef]

46. Pei, J.; Chen, A.; Zhao, L.; Cao, F.; Ding, G.; Xiao, W. One-Pot Synthesis of Hyperoside by a Three-Enzyme Cascade Using a UDP-Galactose Regeneration System. *J. Agric. Food Chem.* **2017**, *65*, 6042–6048. [CrossRef]

47. Weng, C.J.; Yen, G.C. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. *Cancer Metastasis Rev.* **2012**, *31*, 323–351. [CrossRef] [PubMed]

48. Zamora-Ros, R.; Sacerdote, C.; Ricceri, F.; Weiderpass, E.; Roswall, N.; Buckland, G.; St-Jules, D.E.; Overvad, K.; Kyrø, C.; Fagherazzi, G.; et al. Flavonoid and lignan intake in relation to bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Br. J. Cancer* **2014**, *111*, 1870–1880. [CrossRef] [PubMed]

49. Petrick, J.L.; Steck, S.E.; Bradshaw, P.T.; Trivers, K.F.; Abrahamson, P.E.; Engel, L.S.; He, K.; Chow, W.H.; Mayne, S.T.; Risch, H.A.; et al. Dietary intake of flavonoids and oesophageal and gastric cancer: Incidence and survival in the United States of America (USA). *Br. J. Cancer* **2015**, *112*, 1291–1300. [CrossRef] [PubMed]

50. Alam, W.; Khan, H.; Shah, M.A.; Cauli, O.; Saso, L. Kaempferol as a Dietary Anti-Inflammatory Agent: Current Therapeutic Standing. *Molecules* **2020**, *25*, 4073. [CrossRef]

51. Park, U.H.; Hwang, J.T.; Youn, H.; Kim, E.J.; Um, S.J. Kaempferol antagonizes adipogenesis by repressing histone H3K4 methylation at PPARγ target genes. *Biochim. Biophys. Res. Commun.* **2022**, *617*, 345–355. [CrossRef] [PubMed]

52. Beltz, L.A.; Bayer, D.K.; Moss, A.L.; Simet, I.M. Mechanisms of cancer prevention by green and black tea polyphenols. *Crit. Rev. Food Sci. Nutr.* **2015**, *55*, 2983–2987. [CrossRef]

53. Kumar, S.; Pandey, A.K. Chemistry and Biological Activities of Flavonoids: An Overview. *Sci. World J.* **2013**, *2013*, 162750. [CrossRef] [PubMed]

54. Calderón-Montaño, J.M.; Burgos-Morón, E.; Pérez-Guerrero, C.; López-Lázaro, M. A review on the dietary flavonoid kaempferol. *Mini Rev. Med. Chem.* **2011**, *11*, 298–344. [CrossRef]

55. Santos-Buelga, C.; Feliciano, A.S. Flavonoids: From Structure to Health Issues. *Molecules* **2017**, *22*, 477. [CrossRef] [PubMed]

56. Mousdale, D.M.; Coggins, J.R. Subcellular localization of the common shikimate-pathway enzymes in *Pisum sativum* L. *Planta* **1985**, *163*, 241–249. [CrossRef] [PubMed]

57. Jung, E.; Zamir, L.O.; Jensen, R.A. Chloroplasts of higher plants synthesize L-phenylalanine via L-arogenate. *Proc. Natl. Acad. Sci. USA* **1986**, *83*, 7231–7235. [CrossRef] [PubMed]

58. Benesova, M.; Bode, R. Chorismate mutase isozymes from seeds and seedlings of Papaver somniferum. *Phytochemistry* **1992**, *31*, 2983–2987. [CrossRef]

59. Xiao, J. Dietary flavonoid aglycones and their glycosides: Which show better biological significance? *Crit. Rev. Food Sci. Nutr.* **2017**, *57*, 1874–1905. [CrossRef] [PubMed]

60. Santos, M.; Fortunato, R.H.; Spotorno, V.G. Analysis of flavonoid glycosides with potential medicinal properties on Bauhinia uruguayensis and Bauhinia forficata subspesies prunina. *Nat. Prod. Res.* **2019**, *33*, 2574–2578. [CrossRef]

61. Rha, C.S.; Jeong, H.W.; Park, S.; Lee, S.; Jung, Y.S.; Kim, D.O. Antioxidative, Anti-Inflammatory, and Anticancer Effects of Purified Flavonol Glycosides and Aglycones in Green Tea. *Antioxidants* **2019**, *8*, 278. [CrossRef]

62. Viskupicova, J.; Ondrejovic, M.; Sturdik, E. Bioavailability and metabolism of flavonoids. *J. Food Nutr. Res.* **2008**, *47*, 151–162. [CrossRef]

63. Bangar, S.P.; Chaudhary, V.; Sharma, N.; Bansal, V.; Ozogul, F.; Lorenzo, J.M. Kaempferol: A flavonoid with wider biological activities and its applications. *Crit. Rev. Food Sci. Nutr.* **2022**, *1–25*. [CrossRef] [PubMed]

64. Williamson, G.; Kay, C.D.; Crozier, A. The Bioavailability, Transport, and Bioactivity of Dietary Flavonoids: A Review from a Historical Perspective. *Compr. Rev. Food Sci. Food Saf.* **2018**, *17*, 1054–1112. [CrossRef] [PubMed]
65. Németh, K.; Plumb, G.W.; Berrin, J.G.; Juge, N.; Jacob, R.; Naim, H.Y.; Williamson, G.; Swallow, D.M.; Kroon, P.A. Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. *Eur. J. Nutr.* 2003, 42, 29–42. [CrossRef]

66. Nielsen, S.E.; Kall, M.; Justesen, U.; Schou, A.; Dragsted, L.O. Human absorption and excretion of flavonoids after brocoli consumption. *Cancer Lett.* 1997, 114, 173–174. [CrossRef] [PubMed]

67. Terao, J. Dietary flavonoids as antioxidants. *Forum. Nutr.* 2009, 61, 87–94. [CrossRef] [PubMed]

68. Chen, A.Y.; Chen, Y.C. A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention. *Food Chem.* 2013, 138, 2099–2107. [CrossRef] [PubMed]

69. de Vries, J.H.; Hollman, P.C.; Meyboom, S.; Buysman, M.N.; Zock, P.L.; van Staveren, W.A.; Katan, M.B. Plasma concentrations and urinary excretion of the antioxidant flavonoids quercetin and kaempferol as biomarkers for dietary intake. *Am. J. Clin. Nutr.* 1998, 68, 60–65. [CrossRef]

70. Cassidy, A.; Minihane, A.M. The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids. *Am. J. Clin. Nutr.* 2017, 105, 10–22. [CrossRef]

71. Dabeek, W.M.; Marra, M.V. Dietary Quercetin and Kaempferol: Bioavailability and Potential Cardiovascular-Related Bioactivity in Humans. *Nutrients* 2019, 11, 2288. [CrossRef]

72. Cavalier-Smith, T. A revised six-kingdom system of life. *Biol. Rev. Camb. Philos. Soc.* 1998, 73, 203–266. [CrossRef]

73. Markham, K.R.; Geiger, H.; Jaggy, H. Kaempferol-3-O-glucosyl(1-2,1-3 and 1-4)-rhamnoside structures. *Phytochemistry* 1992, 31, 1099–1101. [CrossRef]

74. Tang, Y.; Lou, F.; Wang, J.; Li, Y.; Zhuang, S. Coumaroyl flavonol glycosides from the leaves of Ginkgo biloba. *Phytochemistry* 2001, 58, 1251–1256. [CrossRef]

75. Zheng, W.; Wang, S.Y. Antioxidant Activity and Phenolic Compounds in Selected Herbs. *J. Agric. Food Chem.* 2001, 49, 5165–5170. [CrossRef]

76. Lee, H.S.; Kim, M.J. Selective responses of three Ginkgo biloba leaf-derived constituents on human intestinal bacteria. *J. Agric. Food Chem.* 2002, 50, 1840–1844. [CrossRef]

77. Krauze-Baranowska, M. Flavonoids from the genus Taxus. *Z. Naturforsch C J. Biosci.* 2004, 59, 43–47. [CrossRef] [PubMed]

78. von Moltke, L.L.; Weemhoff, J.L.; Bedir, E.; Khan, I.A.; Harmatz, J.S.; Goldman, P.; Greenblatt, D.J. Inhibition of human cytochromes P450 by components of Ginkgo biloba. *J. Pharm. Pharmacol.* 2004, 56, 1039–1044. [CrossRef] [PubMed]

79. Yoon, K.D.; Jeong, D.G.; Hwang, Y.H.; Ryu, J.M.; Kim, J. Inhibitors of Osteoclast Differentiation from Cephalotaxus koreana. *J. Nat. Prod.* 2007, 70, 2029–2032. [CrossRef]

80. Kwon, S.H.; Nam, J.I.; Kim, S.H.; Kim, J.H.; Yoon, J.H.; Kim, K.S. Kaempferol and quercetin, essential ingredients in Ginkgo biloba extract, inhibit interleukin-1beta-induced MUC5AC gene expression in human airway epithelial cells. *Phytomedicine* 2009, 16, 1708–1712. [CrossRef]

81. Group, T.A.P.; Chase, M.W.; Christenhusz, M.J.M.; Fay, M.F.; Byng, J.W.; Judd, W.S.; Soltis, D.E.; Mabberley, D.J.; Sennikov, A.N.; et al. An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants: APG IV. *Bot. J. Linn. Soc.* 2016, 181, 1–20. [CrossRef]

82. I. P. A community-derived classification for extant lycophytes and ferns. *J. Syst. Evol.* 2016, 54, 563–603. [CrossRef]

83. Christenhusz, M.; Reveal, J.; Farjon, A.; Gardner, M.; Mill, R.; Chase, M. A new classification and linear sequence of extant gymnosperms. *Nov. Magnolia Press Phytotaxa* 2013, 63, 497–502. [CrossRef]

84. Arot Manguro, L.O.; Ugi, I.; Hermann, R.; Lemmen, P. Flavonol and drimane-type sesquiterpene glycosides of Warburgia stuhlmannii leaves. *Phytochemistry* 2003, 63, 1251–1256. [CrossRef]

85. Calzada, F.; Correa-Basurto, J.; Barbosa, E.; Mendez-Luna, D.; Yépez-Mulia, L. Antiprotozoal Constituents from Annona cherimola Miller, a Plant Used in Mexican Traditional Medicine for the Treatment of Diarrhea and Dysentery. *Pharmacogn. Mag.* 2017, 13, 148–152. [CrossRef]

86. Rodriguez Galdón, B.; Rodríguez Rodríguez, E.M.; Díaz Romero, C. Flavonoids in onion cultivars (*Allium cepa* L.). *J. Food Sci.* 2008, 73, C599–C605. [CrossRef] [PubMed]

87. Keyhanian, S.; Stahl-Biskup, E. Phenolic constituents in dried flowers of aloe vera (Aloe barbadensis) and their in vitro antioxidative capacity. *Planta Med.* 2007, 73, 599–602. [CrossRef] [PubMed]

88. Vachářková, A.; Eisenreichová, E.; Haladová, M.; Mucaj, P.; Jůzová, B.; Novotný, L. Potential carcinogenic and inhibitory activity of compounds isolated from *Lilium candidum* Neoplasma. *Phytochemistry* 2000, 63, 313–318. [CrossRef]

89. Francis, J.A.; Rumbeiga, W.; Nair, M.G. Constituents in Easter lily flowers with medicinal activity. *Life Sci.* 2004, 76, 671–683. [CrossRef]

90. Xu, J.; Li, X.; Zhang, P.; Li, Z.L.; Wang, Y. Antiinflammatory constituents from the roots of Smilax bockii varb. *Arch. Pharmacoal Res.* 2005, 28, 395–399. [CrossRef]

91. Jiang, R.-W.; Zhou, J.-R.; Hon, P.-M.; Li, S.-L.; Zhou, Y.; Li, L.-L.; Ye, W.-C.; Xu, H.-X.; Shaw, P.-C.; But, P.P.-H. Lignans from Dysosma versipellis with Inhibitory Effects on Prostate Cancer Cell Lines. *J. Nat. Prod.* 2007, 70, 283–286. [CrossRef]

92. Marín, C.; Boutaleb-Charki, S.; Díaz, J.G.; Huertas, O.; Rosales, M.J.; Pérez-Cordon, G.; Guitierrez-Sánchez, R.; Sánchez-Moreno, M. Antileishmaniasis activity of flavonoids from Consolida oliveriana. *J. Nat. Prod.* 2009, 72, 1069–1074. [CrossRef]
146. Tomaino, A.; Martorana, M.; Arcoraci, T.; Monteleone, D.; Giovinazzo, C.; Sajja, A. Antioxidant activity and phenolic profile of pistachio (*Pistacia vera L.*, variety Bronte) seeds and skins. *Biochimie* 2010, 92, 1115–1122. [CrossRef] [PubMed]

147. Jung, C.H.; Kim, J.H.; Hong, M.H.; Seog, H.M.; Oh, S.H.; Lee, P.J.; Kim, G.J.; Kim, H.M.; Um, J.Y.; Ko, S.-G. Phenolic-rich fraction from Rhus verniciflua Stokes (RVS) suppress inflammatory response via NF-κB and JNK pathway in lipopolysaccharide-induced RAW 264.7 macrophages. *J. Ethnopharmacol.* 2007, 110, 490–497. [CrossRef] [PubMed]

148. Abou-Shoor, M.; Ma, G.E.; Li, X.H.; Koonchanok, M.; Geahlem, R.L.; Chang, C.J. Flavonoids from Koelreuteria henryi and other sources as protein-tyrosine kinase inhibitors. *J. Nat. Prod.* 1993, 56, 967–969. [CrossRef] [PubMed]

149. Lin, W.H.; Deng, Z.W.; Lei, H.M.; Fu, H.Z.; Li, J. Polyphenolic compounds from the leaves of Koelreuteria paniculata Laxm. *J. Asian Nat. Prod. Res.* 2002, 4, 287–295. [CrossRef]

150. Alegrio, L.V.; Braz-Filho, R. Chemical constituents of Simarouba versicolor. *An. Da Acad. Bras. De Ciências* 2002, 74, 415–424. [CrossRef]

151. Salvador, M.J.; Ferreira, E.O.; Mertens-Talcott, S.U.; De Castro, W.V.; Butterweck, V.; Derendorf, H.; Dias, D.A. Isolation and HPLC quantitative analysis of antioxidant flavonoids from Alternanthera tenella Colla. *Z. Für Nat. C* 2006, 61, 19–25. [CrossRef]

152. Aung, H.H.; Chia, L.S.; Goh, N.K.; Chia, T.F.; Ahmed, A.A.; Pare, P.W.; Mabry, T.J. Phenolic constituents from the leaves of the carnivorous plant Nepenthes gracilis. *Fitoterapia* 2002, 73, 445–447. [CrossRef]

153. Kataoka, M.; Hirata, K.; Kunikata, T.; Ushio, S.; Iwaki, K.; Ohashi, K.; Ikeda, M.; Kurimoto, M. Antibacterial action of tryptanthrin and kaempferol, isolated from the indigo plant (*Polygonum tinctorium* Lour.), against Helicobacter pylori-infected Mongolian gerbils. *J. Gastroenterol.* 2001, 36, 5–9. [CrossRef]

154. Parveen, Z.; Deng, Y.; Saeed, M.K.; Dai, R.; Ahamad, W.; Yu, Y.H. Antiinflammatory and analgesic activities of Thesium chinense and its major kaempferol and kaempferol-3-O-glucoside. *Yukagaku Zasshi* 2007, 127, 1275–1279. [CrossRef]

155. Loizzo, M.R.; Said, A.; Tundis, R.; Hawas, U.W.; Rashed, K.; Menichini, F. Antioxidant and antiproliferative activity of Diospyros lotus L. extract and isolated compounds. *Plant Foods Hum. Nutr.* 2009, 64, 264–270. [CrossRef]

156. Crublet, M.-L.; Long, C.; Sévenet, T.; Hadi, H.A.; Lavaud, C. Acylated flavonol glycosides from leaves of Plantonia grandis. *Phytochemistry* 2003, 64, 589–594. [CrossRef]

157. Sumino, M.; Sekine, T.; Ruangrungsi, N.; Igarashi, K.; Ikegami, F. Ardisiphenols and other antioxidant principles from the fruits of Ardisia colorata. *Chem. Pharm. Bull.* 2002, 50, 1484–1487. [CrossRef] [PubMed]

158. Chien, M.M.; Svoboda, G.H.; Schiff, P.L., Jr.; Slatkin, D.J.; Knapp, J.E. Chemical constituents of Echites hirsuta (Apocynaceae). *J. Pharm. Sci.* 1979, 68, 247–249. [CrossRef]

159. Deng, S.; Palu, K.; West, B.J.; Su, C.X.; Zhou, B.N.; Jensen, J.C. Lipoxigenase inhibitory constituents of the fruits of noni (*Morinda citrifolia*) collected in Tahiti. *J. Nat. Prod.* 2007, 70, 859–862. [CrossRef]

160. Cimanga, R.K.; Kambu, K.; Tona, L.; Hermans, N.; Apers, S.; Totté, J.; Pieters, L.; Vlietinck, A.J. Cytotoxicity and in vitro susceptibility of Entamoeba histolytica to Morinda morindoides leaf extracts and its isolated constituents. *J. Ethnopharmacol.* 2006, 107, 83–90. [CrossRef] [PubMed]

161. Majinda, R.R.; Motswaledi, M.; Waigh, R.D.; Waterman, P.G. Phenolic and antibacterial constituents of Vahlia capensis. *Planta Med.* 1997, 63, 268–270. [CrossRef]

162. Ye, M.; Yan, Y.; Guo, D.A. Characterization of phenolic compounds in the Chinese herbal drug Tu-Si-Zi by liquid chromatography coupled to electrospray ionization mass spectrometry. *Rapid Commun. Mass Spectrom.* 2005, 19, 1469–1484. [CrossRef]

163. Umehara, K.; Nemoto, K.; Ohkubo, T.; Miyase, T.; Degawa, M.; Noguchi, H. Isolation of a new 15-membered macrocyclic glycolipid lactone, Cuscutic Resinoside a from the seeds of Cuscuta chinensis: A stimulator of breast cancer cell proliferation. *Planta Med.* 2004, 70, 299–304. [CrossRef]

164. Huang, H.-C.; Syu, K.-Y.; Lin, J.-K. Chemical Composition of Solanum nigrum Linn Extract and Induction of Autophagy by Leaf Water Extract and Its Major Flavonoids in AU565 Breast Cancer Cells. *J. Agric. Food Chem.* 2010, 58, 8699–8708. [CrossRef]

165. Kwak, J.H.; Kang, M.W.; Roh, J.H.; Choi, S.U.; Zee, O.P. Cytotoxic phenolic compounds from Chionanthus retusus. *Arch. Pharmacal Res.* 2009, 32, 1681–1687. [CrossRef] [PubMed]

166. de Laurentis, N.; Stefanizzi, L.; Milillo, M.A.; Santillo, G. Flavonoids from leaves of *Olea europaea* L. cultivars. *Ann. Pharm. Françaises* 1998, 56, 268–273. [CrossRef]

167. Youssef, F.S.; Altyar, A.E.; Omar, A.M.; Ashour, M.L. Phytoconstituents, In Vitro Anti-Infective Activity of Buddleja indica Lam., and In Silico Evaluation of its SARS-CoV-2 Inhibitory Potential. *Front. Pharmacol.* 2021, 12, 619373. [CrossRef] [PubMed]

168. Chatzopoulou, A.; Karioti, A.; Gousiadou, C.; Lax Vivancos, V.; Kyriazopoulos, P.; Golegou, S.; Skaltsa, H. Depsides and Other Polar Constituents from *Origanum dictamnus* L. and Their in Vitro Antimicrobial Activity in Clinical Strains. *J. Agric. Food Chem.* 2010, 58, 6064–6068. [CrossRef] [PubMed]

169. Bai, N.; He, K.; Roller, M.; Lai, C.S.; Shao, X.; Pan, M.H.; Ho, C.T. Flavonoids and phenolic compounds from Rosmarinus officinalis. *J. Agric. Food Chem.* 2010, 58, 5363–5367. [CrossRef] [PubMed]

170. SharifiFar, F.; Yassa, N.; Moazzafarian, V. Bioactivity of major components from the seeds of Bunium persicum (Boiss.) Fedtch. *Pak. J. Pharm. Sci.* 2010, 23, 300–304. [PubMed]

171. Pistelli, L.; Noccioli, C.; Giachi, I.; Dimitrova, B.; Gevrenova, R.; Morelli, I.; Potenza, D. Lupane-triterpenes from Bupleurum flavum. *Nat. Prod. Res.* 2005, 19, 783–788. [CrossRef]
227. Zhang, Y.; Valeriote, F.; Swartz, K.; Chen, B.; Hamann, M.T.; Rodenburg, D.L.; McChesney, J.D.; Shaw, J. HPLC Plasma Assay of a Novel Anti-MRSA Compound, Kaempferol-3-O-Alpha-L-(2',3'-di-p-coumaryloxy)hamnoside, from Sycamore Leaves. Nat. Prod. Commun. 2015, 10, 1383–1386. [CrossRef] [PubMed]

228. Carruthers, N.J.; Stemmer, P.M.; Media, J.; Swartz, K.; Wang, X.; Aube, N.; Hamann, M.T.; Valeriote, F.; Shaw, J. The anti-MRSA compound 3-O-alpha-L-(2',3'-di-p-coumaryloxy)hamnoside (KCR) inhibits protein synthesis in Staphylococcus aureus. J. Proteom. 2020, 210, 103539. [CrossRef] [PubMed]

229. Ishikawa, R.B.; Leitão, M.M.; Kassuya, R.M.; Macorini, L.F.; Moreira, F.M.F.; Cardoso, C.A.L.; Coelho, R.G.; Pott, A.; Gelfuso, G.M.; Croda, J.; et al. Anti-inflammatory, antimycobacterial and genotoxic evaluation of Dolichocarpus dentatus. J. Ethnopharmacol. 2017, 204, 18–25. [CrossRef] [PubMed]

230. Santos, E.D.; Silva-Filho, S.E.; Santos Radai, J.A.; Arena, A.C.; Fraga, T.L.; Lima Cardoso, C.A.; Croda, J.; Leite Kassuya, C.A. Anti-inflammatory properties of ethanolic extract from Vatairea macrocarpa leaves. J. Ethnopharmacol. 2021, 278, 114308. [CrossRef]

231. Asif, M.; Alvi, I.A.; Rehman, S.U. Insight into Acinetobacter baumannii: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect. Drug Resist. 2018, 11, 1249–1260. [CrossRef]

232. Pourhajibagher, M.; Hashemi, F.B.; Pourakbari, B.; Aziemzadeh, M.; Bahador, A. Antimicrobial Resistance of Acinetobacter baumannii to Imipenem in Iran: A Systematic Review and Meta-Analysis. Open Microbiol. / 2016, 10, 32–42. [CrossRef]

233. Qi, L.; Li, H.; Zhang, C.; Liang, B.; Li, J.; Wang, L.; Du, X.; Liu, X.; Qiu, S.; Song, H. Relationship between Antibiotic Resistance, Biofilm Formation, and Biofilm-Specific Resistance in Acinetobacter baumannii. Front. Microbiol. 2016, 7, 483. [CrossRef] [PubMed]

234. Gheorghe-Barbu, I.; Barbu, I.C.; Popa, L.I.; Pircalăbioru, G.G.; Popa, M.; Mărutescu, L.; Nita-Lazar, M.; Banciu, A.; Stoica, C.; Gheorghe, S.; et al. Temporo-spatial variations in resistance determinants and clonality of Acinetobacter baumannii and Pseudomonas aeruginosa strains from Romanian hospitals and wastewaters. Antimicrob. Resist. Infect. Control 2022, 11, 115. [CrossRef]

235. Gu, H.-J.; Sun, Q.-L.; Luo, J.-C.; Zhang, J.; Sun, L. A First Study of the Virulence Potential of a Bacillus subtilis Isolate From Deep-Sea Hydrothermal Vent. Front. Cell Infect. Microbiol. 2019, 9, 183. [CrossRef]

236. Cote, C.K.; Heffron, J.D.; Bozue, J.A.; Welkos, S.L. Chapter 102—Bacillus anthracis and Other Bacillus Species. In Molecular Medical Microbiology, 2nd ed.; Tang, Y.-W., Sussman, M., Liu, D., Poxton, I., Schwartzman, J., Eds.; Academic Press: Boston, MA, USA, 2015; pp. 1789–1844. [CrossRef]

237. Brown, K.L. Control of bacterial spores. Br. Med. Bull. 2000, 56, 158–171. [CrossRef]

238. Spencer, R.C. Bacillus anthracis. J. Clin. Pathol. 2003, 56, 182–187. [CrossRef]

239. Hoffmaster, A.R.; Hill, K.K.; Gee, J.E.; Marston, C.K.; De, B.K.; Popovic, T.; Sue, D.; Wilkins, P.P.; Avashia, S.B.; Drumgoole, R.; et al. Characterization of Bacillus cereus isolates associated with fatal pneumonias: Strains are closely related to Bacillus anthracis and harbor B. anthracis virulence genes. J. Clin. Microbiol. 2006, 44, 3352–3360. [CrossRef] [PubMed]

240. Ramarao, N.; Sanchis, V. The Pore-Forming Haemolysins of Bacillus Cereus: A Review. Toxins 2013, 5, 1119–1139. [CrossRef] [PubMed]

241. Kaper, J.B.; Nataro, J.P.; Mobley, H.L.T. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2004, 2, 123–140. [CrossRef]

242. Nataro, J.P.; Kaper, J.B. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 1998, 11, 413–439. [CrossRef]

243. Pormohammad, A.; Pouriran, R.; Azimi, H.; Goudarzi, M. Prevalence of integron classes in Gram-negative clinical isolated bacteria in Iran: A systematic review and meta-analysis. Iran. J. Basic Med. Sci. 2020, 23, 546–555. [CrossRef] [PubMed]

244. Podschun, R.; Ullmann, U. Pathogenicity and molecular determinants of virulence. Clin. Microbiol. Rev. 2004, 17, 53–94. [CrossRef]

245. Popa, L.; Gheorghe, I.; Barbu, I.; Surleac, M.; Paraschiv, S.; Marutescu, L.; Popa, M.; Avram, I.; Tălăpan, D.; Nita-Lazar, M.; et al. Whole genome sequencing snapshot of multi-drug resistant Klebsiella pneumoniae strains from hospitals and receiving wastewater treatment plants in Southern Romania. PLoS ONE 2020, 15, e0228079. [CrossRef]

246. Smith, I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev. 2003, 16, 463–496. [CrossRef] [PubMed]

247. Mantani, P.; Abubakar, I.; Ariti, C.; Beynon, R.; Pimpin, L.; Fine, P.E.; Rodrigues, L.C.; Smith, P.G.; Lipman, M.; Whiting, P.F.; et al. Protection by BCG vaccine against tuberculosis: A systematic review of randomized controlled trials. Clin. Infect. Dis. 2014, 58, 470–480. [CrossRef] [PubMed]

248. Scriba, T.J.; Netea, M.G.; Ginsberg, A.M. Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Semin. Immunol. 2020, 50, 101431. [CrossRef]

249. Popescu, G.G.; Arghir, O.C.; Fildan, A.P.; Spanu, V.; Cambrea, S.C.; Rafila, A.; Buicu, F.C. Antibiotic resistance of Mycobacterium tuberculosis; mechanism and specific therapeutic response. Farmacia 2020, 68, 197–205. [CrossRef]
342. De Leo, M.; Braca, A.; De Tommasi, N.; Norscia, I.; Morelli, I.; Battinelli, L.; Mazzanti, G. Phenolic compounds from Baseonema acuminate leaves: Isolation and antimicrobial activity. *Planta Med.* 2004, 70, 841–846. [CrossRef] [PubMed]

343. Yordanov, M.; Dimitrova, P.; Patkar, S.; Saso, L.; Ivanovska, N. Inhibition of Candida albicans extracellular enzyme activity by selected natural substances and their application in Candida infection. *Can. J. Microbiol.* 2008, 54, 435–440. [CrossRef] [PubMed]

344. Minetti, C.; Chalmers, R.M.; Beeching, N.J.; Probert, C.; Lamden, K. Giardiasis. *Clin. Microbiol. Rev.* 2003, 16, 535–557. [PubMed]

345. Wolfe, M.S. Giardiasis. *Curr. Trop. Med. Rep.* 2012, 4, 9–20. [PubMed]

346. Yordanov, M.; Dimitrova, P.; Patkar, S.; Saso, L.; Ivanovska, N. Inhibition of Candida albicans extracellular enzyme activity by selected natural substances and their application in Candida infection. *Can. J. Microbiol.* 2008, 54, 435–440. [CrossRef] [PubMed]

347. El-Dib, N.A. Entamoeba histolytica: An Overview. *Curr. Trop. Med. Rep.* 2017, 4, 11–20. [CrossRef]

348. Wolfe, M.S. Giardiasis. *Clin. Microbiol. Rev.* 1992, 5, 93–100. [CrossRef]

349. Minetti, C.; Chalmers, R.M.; Beeching, N.J.; Probert, C.; Lamden, K. Giardiasis. *BMJ* 2016, 355, i5369. [CrossRef]

350. Brün, R.; Blum, J.; Chappuis, F.; Burri, C. Human African trypanosomiasis. *Lancet* 2010, 375, 148–159. [CrossRef]

351. Greenwood, B. The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. *Aust. Fam. Physician* 2012, 41, 782–786.

352. Autino, B.; Noris, A.; Russo, R.; Castelli, F. Epidemiology of malaria in endemic areas. *Int. J. Health Geogr.* 2010, 9, 57. [CrossRef]

353. Abdallah, R.M.; Hammoda, H.M.; Radwan, M.M.; El-Gazzar, N.S.; Wanas, A.S.; ElSohly, M.A.; Abdel-Rahman, N.M.; Sallam, S.M. Phytochemical and pharmacological appraisal of the aerial parts of *Trachyspermum ammi*. *Nat. Prod. Res.* 2021, 35, 102–105. [CrossRef]

354. Alotaibi, A.; Ebiloma, G.U.; Williams, R.; Alfayez, I.A.; Natto, M.J.; Alenezi, S.; Siheri, W.; AlQarni, M.; Igoli, J.O.; Fearnley, J.; et al. Activity of Compounds from Temperate Propolis against Trypanosoma brucei and Leishmania mexicana. *Molecules* 2020, 25, 5232–5244. [CrossRef] [PubMed]

355. Calzada, F.; Meckes, M.; Cedillo-Rivera, R. *In vitro* susceptibility of *Entamoeba histolytica* and *Giardia lamblia* to some medicinal plants used by the people of Southern Mexico. *Phytother. Res.* 1998, 12, 70–72. [CrossRef]

356. Calzada, F.; Meckes, M.; Cedillo-Rivera, R. Antiamoebic and antigiardial activity of plant flavonoids. *Phytother. Res.* 2003, 17, 837–843. [CrossRef] [PubMed]

357. Calzada, F.; Meckes, M.; Cedillo-Rivera, R. Antiamoebic and antigiardial activity of plant flavonoids. *Phytother. Res.* 2003, 17, 837–843. [CrossRef] [PubMed]

358. Meckes, M.; Calzada, F.; Alanis, A.D.; Tapia-Contreras, A.; Cedillo-Rivera, R. Antiprotozoal, antimycobacterial, and anti-inflammatory evaluation of *Cnidoscolus chayamansa* (Mc Vaugh) extract and the isolated compounds. *Biomed. Pharmacother.* 2017, 89, 89–97. [CrossRef] [PubMed]

359. Aragón, M.V.; Queiroz, A.C.; Silva, J.F.M.; Silva, A.E.; Silva, J.K.S.; Silva, G.R.; Silva, E.C.O.; Souza, S.T.; Fonseca, E.J.S.; Câmara, C.A.; et al. Flavonoids induce cell death in Leishmania amazonensis: In vitro characterization by flow cytometry and Raman spectroscopy. *Analyst* 2019, 144, 5232–5244. [CrossRef] [PubMed]

360. Scio, E.; Ribiero, A.; Alves, T.M.; Romanha, A.J.; Dias de Souza Filho, J.; Cordell, G.A.; Romanha, A.J.; Zani, C.L.; Scio, E.; Ribeiro, A.; Alves, T.M.; Romanha, A.J.; Zani, C.L.; *Diterpenes from Alomia acuminatum leaves: Isolation and antimicrobial activity.* *Planta Med.* 2006, 72, 670–674. [CrossRef] [PubMed]

361. Alvar, J.; Vélez, I.D.; Bern, C.; Herrero, M.; Desjeux, P.; Cano, J.; Jannin, J.; den Boer, M. Leishmaniasis worldwide and global estimates of its incidence. *PLOS ONE* 2012, 7, e35671. [CrossRef]

362. Tel, S.; Rissing, A.L.; Nair, S.; Peng, J.; Anderson, T.J.; Du, L.; Powell, D.R.; Mooberry, S.L.; Cicchewicz, R.H. Identification of Compounds with Efficacy against Malaria Parasites from Common North American Plants. *J. Nat. Prod.* 2016, 79, 490–498. [CrossRef]

363. Pérez-González, M.Z.; Gutiérrez-Rebolledo, G.A.; Yépez-Mulia, L.; Rojas-Tomé, I.S.; Luna-Herrera, J.; Jiménez-Arellanes, M.A. Antiprotozoal, antimycobacterial, and anti-inflammatory evaluation of *Cnidioscolus chayamansa* (Mc Vaugh) extract and the isolated compounds. *Biomol. Phamaocother.* 2017, 89, 89–97. [CrossRef] [PubMed]

364. Aratóy, M.V.; Queiroz, A.C.; Silva, J.F.M.; Silva, A.E.; Silva, J.K.S.; Silva, G.R.; Silva, E.C.O.; Souza, S.T.; Fonseca, E.J.S.; Câmara, C.A.; et al. Flavonoids induce cell death in Leishmania amazonensis: In vitro characterization by flow cytometry and Raman spectroscopy. *Analyst* 2019, 144, 5232–5244. [CrossRef] [PubMed]

365. Alotaibi, A.; Ebiloma, G.U.; Williams, R.; Alfaiez, I.A.; Nato, M.J.; Alenezi, S.; Siheri, W.; AlQarni, M.; Igoli, J.O.; Fearnley, J.; et al. Activity of Compounds from Temperate Propolis against *Trypanosoma brucei* and *Leishmania mexicana*. *Molecules* 2021, 26, 3912. [CrossRef] [PubMed]

366. Abdallah, R.M.; Hammoda, H.M.; Radwan, M.M.; El-Gazzar, N.S.; Wanas, A.S.; ElSohly, M.A.; Abdel-Rahman, N.M.; Sallam, S.M. Phytochemical and pharmacological appraisal of the aerial parts of *Latus corniculatus* L. growing in Egypt. *Nat. Prod. Res.* 2021, 35, 5914–5917. [CrossRef] [PubMed]

367. Martínez-Castro, M.; Pacheco-Yépez, J.; Flores-Huerta, N.; Guzmán-Téllez, P.; Jarillo-Luna, R.A.; Cárdenas-Jaramillo, L.M.; Campos-Rodríguez, R.; Shibayama, M. Flavonoids as a Natural Treatment Against *Trypanosoma brucei* and *Leishmania mexicana*. *Front. Cell Infect. Microbiol.* 2018, 8, 209. [CrossRef]

368. Simarro, P.P.; Cecchi, G.; Paone, M.; Franco, J.R.; Díaz, A.; Ruiz, J.A.; Fèvre, E.M.; Courtin, F.; Mattioli, R.C.; Jannin, J.G. The Atlas of human African trypanosomiasis: A contribution to global mapping of neglected tropical diseases. *Int. J. Health Geogr.* 2010, 9, 57. [CrossRef]

369. Desquesnes, M.; Dias, M.L. Mechanical transmission of *Trypanosoma congolense* in cattle by the African tabanid *Atylotus agrestis*. *Exp. Parasitol.* 2003, 105, 226–231. [CrossRef]
455. Ghasemi Pirbalouti, A.; Momeni, M.; Bahmani, M. Ethnobotanical study of medicinal plants used by Kurd tribe in Dehloran and Abdanan Districts, Ilam Province, Iran. *Afr. J. Tradit. Complement. Altern. Med.* **2013**, *10*, 368–385. [CrossRef] [PubMed]

456. Dexter, D.F.; Martin, K.; Travis, L. Prehistoric plant use at beaver creek rock shelter, Southwestern Montana, USA. *Ethnobot. Res. Appl.* **2014**, *12*, 355–384. [CrossRef]

457. Chermat, S.; Gharzouli, R. Ethnobotanical study of medicinal flora in the North East of Algeria-An empirical knowledge in Djebel Zdimm (Setif). *J. Mater. Sci. Eng.* **2015**, *5*, 50–59.

458. Lakhdari, W.; Dehliz, A.; Acheuk, F.; Mlik, R.; Hammi, H.; DOUMANDJI-MITICHE, B.; Gheriani, S.; Berrekbia, M.; Guermit, K.; Chergui, S. Ethnobotanical study of some plants used in traditional medicine in the region of Oued Righ (Algerian Sahara). *J. Med. Plants* **2016**, *4*, 204–211.

459. Sun, L.; Liao, L.; Wang, B. Potential Antinociceptive Effects of Chinese Propolis and Identification on Its Active Compounds. *J. Immunol. Res.* **2018**, *2018*, 5429543. [CrossRef]

460. Zhu, W.; Chen, M.; Shou, Q.; Li, Y.; Hu, F. Biological activities of chinese propolis and brazilian propolis on streptozotocin-induced type 1 diabetes mellitus in rats. *Evid. -Based Complement. Altern. Med.* **2011**, *2011*, 468529. [CrossRef]

461. Periferakis, A.; Bolocan, A.; Ion, D. A Review of Innovation in Medicine. *Technol. Innov. Life Sci.* **2022**, *1*, 42–48. [CrossRef]

462. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. *J. Nat. Prod.* **2020**, *83*, 770–803. [CrossRef]

463. Schauer, C.; Mihai, L.; Bădarău, I.; Caruntu, C. Emerging applications of some important natural compounds in the field of oncology. *Farmacia* **2020**, *68*, 984–991. [CrossRef]

464. Dehelean, C.A.; Marcovici, I.; Soica, C.; Mioc, M.; Coricovac, D.; Iurciuc, S.; Cretu, O.M.; Pinzarul, I. Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy. *Molecules* **2021**, *26*, 1109. [CrossRef]